HK1207859B - Dna-pk inhibitors - Google Patents

Description

DNA-PK inhibitors

Technical Field

The present invention relates to compounds useful as inhibitors of DNA-dependent protein kinases (DNA-PK). The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of cancer.

Background

Ionizing Radiation (IR) induces a variety of DNA damage, of which Double Strand Breaks (DSBs) are the most cytotoxic. These DSBs can lead to cell death via apoptotic and/or mitotic catastrophes if not rapidly and completely repaired. In addition to IR, certain chemotherapeutic agents (including topoisomerase II inhibitors, bleomycin and doxorubicin) also cause DSB. These DNA lesions respond to the network through DNA damageTriggering a complex series of signals that act to repair damaged DNA and maintain cell viability and genomic stability. In mammalian cells, the major repair pathway of DSBs is the non-homologous end joining pathway (NHEJ). This pathway functions regardless of the phase of the cell cycle and does not require a template to reconnect the fragmented DNA ends. NHEJ requires the cooperation of many proteins and signaling pathways. The core NHEJ mechanism consists of the Ku70/80 heterodimer and the catalytic subunit of DNA-dependent protein kinase (DNA-PKc), which together constitute the active DNA-PK enzyme complex. DNA-PKc is a member of the phosphatidylinositol 3-kinase related kinase (PIKK) family of serine/threonine protein kinases, which also includes ataxia telangiectasia mutated kinase (ATM), ataxia telangiectasia and Rad3 related kinase (ATR), mTOR and the four PI3K isoforms. However, although DNA-PKc belongs to the same family of protein kinases as ATM and ATR, the latter two kinases function through the Homologous Recombination (HR) pathway to repair DNA damage and are limited to the S phase and G phase of the cell cycle₂And (4) period. Although ATM is also recruited to sites of DSBs, ATR is recruited to sites of single-stranded DNA breaks.

NHEJ is thought to develop through three key steps: identifying the DSB; performing DNA processing to remove non-ligatable ends or other forms of damage at the endpoints; and finally joining the DNA ends. Identifying the DSB is performed by: ku heterodimer binds to incomplete (scrambled) DNA ends, then recruits two molecules of DNA-PKc to the adjacent side of the DSB; this serves to protect the break endpoint until additional processing enzymes are recruited. Recent data supports the hypothesis that: the DNA-PKc phosphorylates the processing enzyme Artemis and itself to prepare the DNA ends for additional processing. In some cases, a DNA polymerase may be required to synthesize new ends prior to the ligation step. Autophosphorylation of DNA-PKc is believed to induce a conformational change that opens the central DNA binding cavity, releasing the DNA-PKc from the DNA, and aiding in the final religation of the DNA ends.

DNA-PK has been known for some time^+/-Mice are highly sensitive to the effects of IR andand some non-selective small molecule inhibitors of DNA-PKc can radiosensitize a wide panel of genetic backgrounds of multiple tumor cell types. Although inhibition of DNA-PK would be expected to radiosensitize normal cells to some extent, it has been observed that this degree of sensitization is lower than that of tumor cells, probably due to the fact that: tumor cells have a high basal level of endogenous replication stress and DNA damage (oncogene-induced replication stress) and the DNA repair mechanisms are inefficient in tumor cells. Most importantly, recent advances in DNA-PK inhibitors in combination with precise delivery of focused IR, including image-guided rt (igrt) and intensity-modulated rt (imrt), will improve the therapeutic window, better sparing normal tissues.

Inhibition of DNA-PK activity causes effects in both periodic and non-periodic cells. This is extremely important because most cells in a solid tumor are inactive to replicate at any given time, which limits the efficacy of many agents targeting the cell cycle. Also of interest is a recent report that suggests a strong link between inhibition of the NHEJ pathway and the ability to kill Cancer Stem Cells (CSCs) that are traditionally resistant to radioactivity. It has been shown in some tumor cells that DSBs in dormant CSCs activate DNA repair primarily through the NHEJ pathway; CSCs are believed to be normally in the quiescent phase of the cell cycle. This may explain why half of cancer patients may experience local or distant tumor recurrence despite treatment, as current strategies are not able to effectively target CSCs. DNA-PK inhibitors may have the ability to increase the sensitivity of these potential metastatic progenitor cells to IR effects as well as to select DSB-inducing chemotherapeutic agents.

Given that DNA-PK is involved in DNA repair processes, the use of specific DNA-PK inhibitory drugs would serve as agents that could enhance the efficacy of both cancer chemotherapy and radiotherapy. Therefore, it would be desirable to develop compounds that are useful as inhibitors of DNA-PK.

Disclosure of Invention

It has been found that the compounds of the present invention and pharmaceutically acceptable compositions thereof are effective as inhibitors of DNA-PK. Accordingly, the invention features a compound having the general formula:

wherein R is¹Each of Q, ring a, and ring B is as defined herein.

The invention also provides pharmaceutical compositions comprising a compound of formula I together with a pharmaceutically acceptable carrier, adjuvant or vehicle. These compounds and pharmaceutical compositions are useful for treating or lessening the severity of cancer.

The compounds and compositions provided by the present invention are also useful for the study of DNA-PK in biological and pathological phenomena; studying intracellular signal transduction pathways mediated by such kinases; and comparative evaluation of novel kinase inhibitors.

Detailed Description

Definitions and general terms

As used herein, the following definitions shall apply unless otherwise indicated. For the purposes of the present invention, the chemical Elements are according to the Periodic Table of the Elements, CAS version (Periodic Table of Elements, CAS version) and handbook of Chemistry and Physics,75^thEd.1994 (handbook of chemistry and Physics,75 th edition, 1994). In addition, the general principles of organic chemistry are described in the following documents: "Organic Chemistry", ThomasSorrell, University Science Books, Sausaltio (Soxhlet University Science Books): 1999; "March's Advanced Organic Chemistry (March Advanced Organic Chemistry)", 5 th edition, Smith, M.B. and March, J. eds, John Wiley&Sons, New York (New Yohn Willi parent-child publishing company, N.Y.: 2001), from which will be describedThe entire contents of the above documents are incorporated by reference.

As described herein, the compounds of the present invention may be optionally substituted with one or more substituents, such as those generally set forth above or as exemplified by specific classes, subclasses, and materials of the invention. It is to be understood that the phrase "optionally substituted" may be used interchangeably with the phrase "substituted or unsubstituted. Generally, the term "substituted," whether preceded by the term "optionally" or not, means that one or more hydrogen groups in a given structure are replaced with the indicated substituent. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group. When more than one position in a given structure can be substituted with more than one substituent selected from a specified group, the substituents at each position can be the same or different.

As used herein, when the term "optionally substituted" precedes a list, the term refers to all of the subsequently substitutable groups in the list. For example, if X is halogen; optionally substituted C_1-3Alkyl or phenyl, X may be optionally substituted alkyl or optionally substituted phenyl. Likewise, if the term "optionally substituted" follows a list, the term also refers to all of the substitutable groups in the preceding list, unless otherwise indicated. For example: if X is halogen, C_1-3Alkyl or phenyl, wherein X is optionally J^XSubstituted, then C_1-3Both alkyl and phenyl groups can optionally be substituted by J^XAnd (4) substitution. As will be apparent to one of ordinary skill in the art, such as H, halogen, NO₂、CN、NH₂OH or OCF₃Such groups are not intended to be included because they are not substitutable groups. It will also be apparent to the skilled person that the heteroaryl or heterocyclyl ring containing an NH group may optionally be substituted by replacing a hydrogen atom with said substituent. A substituent group or structure is unsubstituted if it is not specified or defined as "optionally substituted".

Combinations of substituents envisioned by the present invention are preferably those that are capable of forming stable or chemically feasible compounds. The term "stable" as used herein means that the compound is not substantially altered when subjected to conditions which allow its production, detection and preferably its recovery, purification and use for one or more of the purposes disclosed herein. In some embodiments, a stabilizing compound or chemically feasible compound is a compound that is not substantially altered when held at 40 ℃ or less for at least one week in the absence of moisture or other chemically reactive conditions.

The term "alkyl" or "alkyl group" as used herein means a straight (i.e., unbranched) or branched, substituted or unsubstituted, fully saturated hydrocarbon chain. Unless otherwise indicated, alkyl groups contain 1-8 carbon atoms. In some embodiments, the alkyl group contains 1-6 carbon atoms, and in other embodiments, the alkyl group contains 1-4 carbon atoms (denoted as "C_1-4Alkyl "). In other embodiments, the alkyl group is characterized as "C_0-4Alkyl ", which represents a covalent bond or C_1-4An alkyl chain. Examples of alkyl groups include methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl and tert-butyl. The term "alkylene" as used herein represents a saturated divalent straight or branched chain hydrocarbon group and is exemplified by methylene, ethylene, isopropylene and the like. The term "alkylidene" as used herein represents a divalent straight chain alkyl linker. The term "alkenyl" as used herein represents a monovalent straight or branched chain hydrocarbon group containing one or more carbon-carbon double bonds. The term "alkynyl" as used herein represents a monovalent straight or branched chain hydrocarbon radical containing one or more carbon-carbon triple bonds.

The term "cycloalkyl" (or "carbocycle") refers to a monocyclic C₃-C₈Hydrocarbons or bicyclic radicals C₈-C₁₂A hydrocarbon that is fully saturated and has a single point of attachment to the rest of the molecule, and wherein any individual ring in the bicyclic ring system has from 3 to 7 members. Suitable cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.

The term "heterocycle", "heterocyclyl", "heterocycloalkyl", or "heterocyclic" as used herein refers to a monocyclic, bicyclic, or tricyclic ring system in which at least one ring in the ring system contains one or more heteroatoms, which may be the same or different, and is fully saturated or contains one or more units of unsaturation, but which is not aromatic and has a single point of attachment to the rest of the molecule. In some embodiments, a "heterocycle", "heterocyclyl", "heterocycloalkyl", or "heterocyclic" group has three to fourteen ring members in which one or more ring members is a heteroatom independently selected from oxygen, sulfur, nitrogen, or phosphorus, and each ring in the ring system contains 3 to 8 ring members.

Examples of heterocycles include, but are not limited to, the following monocyclic rings: 2-tetrahydrofuryl, 3-tetrahydrofuryl, 2-tetrahydrothienyl, 3-tetrahydrothienyl, 2-morpholinyl, 3-morpholinyl, 4-morpholinyl, 2-thiomorpholinyl, 3-thiomorpholinyl, 4-thiomorpholinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-tetrahydropiperazinyl, 2-tetrahydropiperazinyl, 3-tetrahydropiperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 5-pyrazolinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2-thiazolidinyl, 3-pyrrolidinyl, 3-morpholinyl, 3-pyrrolidinyl, 3-morpholinyl, 4-thiazolidinyl, 1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 5-imidazolidinyl; and the following bicyclic rings: 3-1H-benzimidazol-2-one, 3- (1-alkyl) -benzimidazol-2-one, indolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzothiophenyl, benzodithiane, and 1, 3-dihydro-imidazol-2-one.

The term "heteroatom" means one or more of oxygen, sulfur, nitrogen or phosphorus, including any oxidized form of nitrogen, sulfur or phosphorus; quaternized forms of any basic nitrogen; or a heterocyclic substitutable nitrogen, e.g. N (as in 3, 4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR⁺(as in N-substituted pyrrolidinyl).

The term "unsaturated" as used herein means that the moiety (moiey) has one or more units of unsaturation.

The term "alkoxy" or "thioalkyl" as used herein, refers to an alkyl group, as previously defined, attached to the main carbon chain through an oxygen ("alkoxy") or sulfur ("thioalkyl") atom.

The terms "haloalkyl", "haloalkenyl" and "haloalkoxy" mean alkyl, alkenyl or alkoxy optionally substituted with one or more halogen atoms. The term "halogen" means F, Cl, Br or I.

The term "aryl", used alone or as part of a larger moiety (as in "aralkyl", "aralkoxy", or "aryloxyalkyl"), refers to a monocyclic, bicyclic, or tricyclic carbocyclic ring system having a total of six to fourteen ring members, wherein the ring system has a single point of attachment to the rest of the molecule, at least one ring in the ring system is aromatic and wherein each ring in the ring system contains 4 to 7 ring members. The term "aryl" is used interchangeably with the term "aryl ring". Examples of aryl rings include phenyl, naphthyl, and anthracene.

The term "heteroaryl", used alone or as part of a larger moiety (as in "heteroaralkyl" or "heteroarylalkoxy"), refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, wherein the ring system has a single point of attachment to the rest of the molecule, at least one ring in the ring system is aromatic, at least one ring in the ring system contains one or more heteroatoms independently selected from nitrogen, oxygen, sulfur, or phosphorus, and wherein each ring in the ring system contains 4 to 7 ring members. The term "heteroaryl" may be used interchangeably with the term "heteroaryl ring" or the term "heteroaromatic".

Additional examples of heteroaryl rings include the following monocyclic rings: 2-furyl, 3-furyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoimidazolylAzolyl, 4-isoAzolyl, 5-isoAzolyl, 2-Azolyl, 4-Azolyl, 5-Oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g. 3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (e.g. 5-tetrazolyl), triazolyl (e.g. 2-triazolyl and 5-triazolyl), 2-thienyl, 3-thienyl, pyrazolyl (e.g. 2-pyrazolyl), isothiazolyl, 1,2,3-Oxadiazolyl, 1,2,5-Oxadiazolyl, 1,2,4-Oxadiazolyl, 1,2, 3-triazolyl, 1,2, 3-thiadiazolyl, 1,3, 4-thiadiazolyl, 1,2, 5-thiadiazolyl, pyrazinyl, 1,3, 5-triazinyl, and the following bicyclic rings: benzimidazolyl, benzofuranyl, benzothienyl, indolyl (e.g., 2-indolyl), purinyl, quinolyl (e.g., 2-quinolyl, 3-quinolyl, 4-quinolyl), and isoquinolyl (e.g., 1-isoquinolyl, 3-isoquinolyl, or 4-isoquinolyl).

As described herein, a bond drawn from a substituent to the center of one ring within a polycyclic ring system (as shown below) represents the substitution of the substituent at any substitutable position in any of the rings within the polycyclic ring system. For example, structure a represents a possible substitution in any of the positions shown in structure b.

This also applies to polycyclic ring systems fused to optional ring systems (which will be indicated by dashed lines). For example, in structure c, X is an optional substituent for both ring a and ring B.

However, if two rings in a polycyclic ring system each have a different substituent drawn from the center of each ring, each substituent represents only the substituent on the ring to which it is attached unless otherwise specified. For example, in structure d, Y is only an optional substituent for ring a and X is only an optional substituent for ring B.

The term "protecting group" as used herein represents those groups intended to protect functional groups (e.g., alcohols, amines, carboxyl groups, carbonyl groups, etc.) from undesired reactions during synthetic procedures. Commonly used protecting groups are disclosed in the following documents: greene and Wuts, Protective Groups In Organic Synthesis (Protective Groups In Organic Synthesis), 3 rd edition (New York John Willi father publishing Co., 1999), which is incorporated herein by reference. Examples of nitrogen protecting groups include: acyl, aroyl or carbamoyl radicals such as the formyl, acetyl, propionyl, pivaloyl, tert-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthaloyl, o-nitrophenoxyacetyl, alpha-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl and chiral auxiliaries such as protected or unprotected D, L or D, L-amino acids such as alanine, leucine, phenylalanine, etc.; sulfonyl groups such as benzenesulfonyl, p-toluenesulfonyl and the like; a carbamate group such as benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3, 4-dimethoxybenzyloxycarbonyl, 3, 5-dimethoxybenzyloxycarbonyl, 2, 4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4, 5-dimethoxybenzyloxycarbonyl, 3,4, 5-trimethoxybenzyloxycarbonyl, 1- (p-biphenylyl) -1-methylethoxycarbonyl, alpha-dimethyl-3, 5-dimethoxybenzyloxycarbonyl, diphenylmethoxycarbonyl, tert-butoxycarbonyl, diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, N-ethyloxycarbonyl, N-methyloxycarbonyl, 2,2, 2-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl, cyclopentyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl, phenylthiocarbonyl and the like, aralkyl groups such as benzyl, triphenylmethyl, benzyloxymethyl and the like and silyl groups such as trimethylsilyl and the like. Preferred N-protecting groups are formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, alanyl, phenylsulfonyl, benzyl, t-butyloxycarbonyl (Boc) and benzyloxycarbonyl (Cbz).

Unless otherwise depicted or described, a recited structure herein is intended to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers of each asymmetric center. Thus, individual stereochemical isomers as well as enantiomeric, diastereomeric and geometric (or conformational) mixtures of the compounds of the present invention are within the scope of the invention. Has been drawn with stereochemical centres (usually by using shaded bondsOr bold keyDefinitions) are stereochemically pure, but the absolute stereochemistry is not yet defined. Such compounds may have the R or S configuration. In those cases where absolute configuration has been determined, the chiral center is labeled with (R) or (S) in the plot.

Unless otherwise indicated, all tautomeric forms of the compounds of the invention are within the scope of the invention. In addition, unless otherwise specified, the structures depicted herein are also intended to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, having the structure of the invention except that deuterium or tritium is substituted for hydrogen or enriched¹³C-or¹⁴Carbon-substituted compounds of C are within the scope of the invention. Such compounds may be used, for example, as analytical tools, probes in bioassays, or as DNA-PK inhibitors with improved therapeutic properties.

Description of the Compounds of the invention

In one aspect, the invention features a compound having the formula:

wherein

Q is N or CH;

R¹is hydrogen, CH₃、CH₂CH₃Or R is¹And the carbon to which it is bonded to form C ═ CH₂A group;

ring a is a ring system selected from:

R^A1is hydrogen, halogen, C_1-4Alkyl radical, C_0-4alkyl-C_3-6Cycloalkyl radical, C_0-4alkyl-OR^A1a、C_0-4alkyl-SR^A1a、C_0-4alkyl-C (O) N (R)^A1a)₂、C_0-4alkyl-CN, C_0-4alkyl-S (O) -C_1-4Alkyl radical, C_0-4alkyl-S (O)₂-C_1-4Alkyl radical, C_0-4alkyl-C (O) OR^A1b、C_0-4alkyl-C (O) C_1-4Alkyl radical, C_0-4alkyl-N (R)^A1b)C(O)R^A1a、C_0-4alkyl-N (R)^A1b)S(O)₂R^A1a、C_0-4alkyl-N (R)^A1a)₂、C_0-4alkyl-N (R)^A1b) (3-to 6-membered cycloalkyl), C_0-4alkyl-N (R)^A1b) (4-6-membered heterocyclic group), N (R)^A1b)C_2-4alkyl-N (R)^A1a)₂、N(R^A1b)C_2-4alkyl-OR^A1a、N(R^A1b)C_1-4Alkyl- (5-10 membered heteroaryl), N (R)^A1b)C_1-4Alkyl- (4-6 membered heterocyclyl), N (R)^A1b)C_2-4alkyl-N (R)^A1b)C(O)R^A1a、C_0-4alkyl-N (R)^A1b)C(O)C_1-4Alkyl radical, C_0-4alkyl-N (R)^A1b)C(O)OC_1-4Alkyl radical, C_0-4Alkyl- (phenyl), C_0-4Alkyl- (3-10 membered heterocyclyl), C_0-4alkyl-C (O) - (4-6 membered heterocyclyl), C_0-4alkyl-O-C_0-4Alkyl- (4-6 membered heterocyclyl), C_0-4Alkyl- (5-6 membered heteroaryl), C_0-4alkyl-C (O) - (5-6 membered heteroaryl), C_0-4alkyl-O-C_0-4Alkyl- (5-6 membered heteroaryl), C_0-4alkyl-N (R)^A1a) (4-6 membered heterocyclic group) or C_0-4alkyl-N (R)^A1b) (5-6 membered heteroaryl), wherein R is^A1Each of the heterocyclic groups is selected from aziridinyl, oxetanyl, tetrahydropyran, tetrahydrofuryl, dioxanyl, dioxolanyl, azetidinyl, pyrrolidinyl, pyrrolidinonyl, pyridonylPyrrolidinedionyl, morpholinyl, piperidinyl, piperazinyl, piperazinonyl, tetrahydrothiophenedioxy, 1-dioxothietanyl, 2-oxa-6-azaspiro [3.4 ]]An octyl or isoindolinone group, wherein R is^A1Each of the heteroaryl groups is selected from the group consisting of furyl, tetrahydropyranyl, imidazolyl, benzimidazolyl, imidazolyl, methyl, ethyl, propyl, isopropyl,Azolyl group,(iii) a ring system of oxadiazolyl, thiazolyl, pyrazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, triazolyl or tetrazolyl, and wherein said R^A1Each of the alkyl, cycloalkyl, phenyl, heterocyclyl or heteroaryl groups is optionally substituted by up to three F atoms, up to two C atoms_1-2Alkyl radical, one C_3-6Cycloalkyl, one phenyl, one benzyl, one alkenyl-C_0-2Alkyl, an alkynyl-C_0-2Alkyl, up to two C_0-2alkyl-OR^A1bRadical, a C_0-2alkyl-N (R)^A1b)₂Radical, an SC_1-4Alkyl, an S (O)₂C_1-4Alkyl, one C (O) R^A1bA radical, a C (O) OR^A1bA radical, a C (O) N (R)^A1b)₂A radical, a-CN group or a C selected from the group consisting of oxetanyl, tetrahydrofuryl, tetrahydropyran, piperidinyl and morpholinyl_4-6Substituted with a heterocyclic ring system;

each R^A1aIndependently of each other is hydrogen, C_1-4Alkyl radical, C_3-6Cycloalkyl, C selected from oxetanyl, tetrahydrofuryl, tetrahydropyran, pyrrolidinyl or piperidinyl_4-6Heterocyclyl, C selected from imidazolyl, triazolyl, tetrazolyl, pyrazolyl, thiophenyl, thiazolyl, pyridyl, pyrimidinyl or pyrazinyl_5-6Heteroaryl, or two R^A1aAnd the intervening nitrogen atom form a group selected from aziridinyl, azetidinyl, pyrrolidinyl, pyrrolidinonyl, piperidinyl, piperidinonyl, tetrahydropyridinyl, piperazinyl, or3-6 membered heterocyclic ring of morpholinyl, wherein said R^A1aEach of the alkyl, cycloalkyl, heterocyclyl or heteroaryl groups is optionally substituted by up to three F atoms, up to two C atoms_1-2Alkyl radical, one C_3-6Cycloalkyl, up to two C_0-2alkyl-OR^A1bRadical, a C_0-2alkyl-N (R)^A1b)₂Radical, an SC_1-4Alkyl, one C (O) R^A1bA radical, a C (O) OR^A1bA radical, a C (O) N (R)^A1b)₂Substituted by a group or a-CN group;

each R^A1bIndependently of each other is hydrogen, C_1-2Alkyl or C_3-4A cycloalkyl group;

R^A2is hydrogen, C_1-4Alkyl radical, C_0-4alkyl-C_3-6Cycloalkyl radical, C_0-2Alkyl- (4-6 membered) heterocyclic group, C_2-4alkyl-OR^A2a、C_0-2alkyl-C (O) N (R)^A2a)₂、C_0-2alkyl-S (O)₂-C_1-4Alkyl radical, C_0-2alkyl-C (O) OC_1-4Alkyl radical, C_0-2alkyl-C (O) - (4-6 membered) heterocyclyl, wherein each of the heterocyclyl is selected from oxetanyl, tetrahydropyran, tetrahydrofuranyl, dioxacyclohexyl, dioxolanyl, azetidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolidinedionyl, morpholinyl, piperidinyl, piperazinyl, piperazinonyl, or 1, 1-dioxothiacyclobutyl, and the R^A2Each of the radicals other than hydrogen being optionally substituted by up to three F atoms, up to two C atoms_1-2Alkyl radical, one C_3-6Cycloalkyl, one alkenyl-C_0-2Alkyl, an alkynyl-C_0-2Alkyl, up to two OR^A2bRadical, a C_0-2alkyl-N (R)^A2b)₂Radical, an SC_1-4Alkyl, an S (O)₂C_1-4Alkyl, one C (O) R^A2bA radical, a C (O) OR^A2bA radical, a C (O) N (R)^A2b)₂Substituted by a group or a-CN group;

each R^A2aIndependently of hydrogen、C_1-4Alkyl, C selected from imidazolyl, triazolyl, tetrazolyl, pyrazolyl, thiophenyl, thiazolyl, pyridyl, pyrimidinyl or pyrazinyl_5-6Heteroaryl, or two R^A2aAnd the intervening nitrogen atom form a 3-6 membered heterocyclic ring selected from aziridinyl, azetidinyl, pyrrolidinyl, pyrrolidinonyl, piperidinyl, piperidinonyl, tetrahydropyridinyl, piperazinyl, or morpholinyl;

each R^A2bIndependently of each other is hydrogen, C_1-4Alkyl or C_3-4A cycloalkyl group;

R^A3is hydrogen or C_1-2An alkyl group;

each R^A4Independently of each other is deuterium, halogen, CN, C_1-4Alkyl or OC_1-4Alkyl radical, wherein each R^A4Alkyl is optionally substituted by up to 3F atoms, two non-geminal OH groups, or an OC_1-2Alkyl substitution, or two R^A4Together with the intervening saturated carbon atom form a spirocyclopropyl or cyclobutyl ring;

n is 0 to 3;

ring B is a ring system selected from:

R^B1is hydrogen, C_1-4Alkyl group, (CH)₂)_0-1C_3-6Cycloalkyl, C (O) C_1-2Alkyl group, (CH)₂)_0-1- (4-to 6-membered) heterocyclyl ring, wherein the heterocyclyl ring is selected from oxetanyl, tetrahydrofuranyl, tetrahydropyran, dioxacyclohexyl, dioxanyl or pyrrolidinonyl, phenyl, benzyl or (CH)₂)_1-2(5-6 membered) heteroaryl ring, wherein the heteroaryl ring is selected from pyridyl, trifluoromethyl,Imidazolyl or pyrazolyl, and wherein said R^B1Each of alkyl, cycloalkyl, phenyl, benzyl, heterocyclyl or heteroaryl is optionally substituted with up to 3F atoms, up to two C atoms_1-2Alkyl, two non-geminal OH groups or an OC_1-2Alkyl substitution;

R^B2is hydrogen, C_1-4Alkyl, OC_1-4An alkyl group;

each R^B3Independently of one another is hydrogen, halogen, C_1-4Alkyl radical, C_2-4Alkenyl radical, C_2-4Alkynyl, CN, C (O) H, C (O) C_1-4Alkyl, C (O) OC_1-4Alkyl, C (O) C_1-4Alkyl, C (O) NH₂、C(O)NHC_1-4Alkyl, C (O) NH (CH)₂)_0-1C_3-6Cycloalkyl, C (O) NHCH₂Oxetanyl, C (O) NHCH₂Tetrahydrofuranyl, C (O) NHCH₂Tetrahydropyranyl, C (O) NH phenyl, C (O) NH benzyl, C (O) NHOH, C (O) NHOC_1-4Alkyl, C (O) NHO (CH)₂)_0-1C_3-6Cycloalkyl, C (O) NHO (CH)₂)_0-1Oxetanyl, C (O) NHO (CH)₂)_0-1Tetrahydrofuranyl, C (O) NHO (CH)₂)_0-1Tetrahydropyranyl, C (O) NHO phenyl, C (O) NHO benzyl, NH₂、NHC(O)C_1-4Alkyl, OC_1-4Alkyl, SC_1-4Alkyl, S (O) C_1-4Alkyl or is selected from the group consisting of furyl, thiophenyl, imidazolyl, pyrrolyl, pyrazolyl anda 5-membered heteroaryl ring system of oxadiazolyl, wherein each R^B3The radicals, other than hydrogen or halogen, being optionally substituted by Cl, up to three F atoms, up to two non-geminal OH groups, up to two OC groups_1-2Alkyl, one NH₂A NHC_1-2Alkyl, one NHC (O) C_1-2Alkyl or an N (C)_1-2Alkyl radical)₂Substitution;

each R^B4Independently of one another is hydrogen, halogen, C_1-4Alkyl, OC_1-4Alkyl, SC_1-4Alkyl, aryl, heteroaryl, and heteroaryl,NH₂、NH(C_1-4Alkyl group), N (C)_1-4Alkyl radical)₂、NHC(O)C_1-4Alkyl, C (O) OH, C (O) OC_1-4Alkyl, C (O) NH₂、C(O)NHC_1-4Alkyl, C (O) N (C)_1-4Alkyl radical)₂CN, morpholinyl ring or imidazolyl ring, wherein each R is^B4Alkyl is optionally substituted by up to 3F atoms, two non-geminal OH groups or one OC_1-2Alkyl substitution;

R^B5is hydrogen, C_1-4Alkyl, C (O) C_1-4Alkyl, C (O) OC_1-4Alkyl, C (O) NH₂、C(O)NHC_1-4Alkyl or C (O) N (C)_1-4Alkyl radical)₂Wherein said R is^B5Alkyl is optionally substituted by up to 3F atoms, two non-geminal OH groups or one OC_1-2Alkyl is substituted, and

R^B6is F or C_1-2Alkyl, or two R^B6And the intervening carbon atoms form a spiro cyclopropyl ring or a spiro butyl ring.

In one embodiment, the compound has the formula:

in one embodiment, the compound has one of the following formulas:

in one embodiment, the compound has one of the following formulas:

in one embodiment, the compound has one of the following formulas:

in further embodiments of any of the compounds of formulas I-A-1 through I-A-3, I-A-6 through I-A-7, or I-A-9 through I-A-10, R^A1Is C_1-4Alkyl, OC_1-4Alkyl or N (R)^A1a)₂Wherein each R is^A1aIndependently is hydrogen or C_1-4Alkyl, or two R^A1aAnd the intervening nitrogen atom form a 3-6 membered heterocyclic ring selected from aziridinyl, azetidinyl, pyrrolidinyl, pyrrolidinonyl, piperidinyl, piperidinonyl, tetrahydropyridinyl, piperazinyl or morpholinyl, wherein said R is^A1Each of the alkyl or heterocyclyl groups is optionally substituted by up to three F atoms, up to three²H atom, at most two C_1-2Alkyl radical, one C_3-6Cycloalkyl, up to two C_0-2alkyl-OR^A1bRadical, a C_0-2alkyl-N (R)^A1b)₂Radical, an SC_1-4Alkyl, one C (O) R^A1bA radical, a C (O) OR^A1bA radical, a C (O) N (R)^A1b)₂Substituted by radicals or one-CN group, in which each R is^A1bIndependently of each other is hydrogen, C_1-2Alkyl or C_3-4A cycloalkyl group.

In one embodiment, the compound has one of the following formulas:

in one embodiment, the compound has the formula:

in one embodiment, the compound has one of the following formulas:

in one embodiment, the compound has one of the following formulas:

in one embodiment, the compound has the formula:

in one embodiment, the compound has one of the following formulas:

in one embodiment, the compound has one of the following formulas:

in one embodiment, the compound has one of the following formulas:

in one embodiment, the compound has one of the following formulas:

in one embodiment, the compound has the formula:

in one embodiment, the compound has one of the following formulas:

in one embodiment, the compound has the formula:

in one embodiment, the compound has the formula:

in one embodiment, the compound has the formula:

in one embodiment, the compound has one of the following formulas:

in one embodiment, the compound has one of the following formulas:

in one embodiment, the compound has the formula:

in one embodiment, the compound has the formula:

in one embodiment, the compound has the formula:

in one embodiment, the compound has one of the following formulas:

in one embodiment, the compound has one of the following formulas:

in one embodiment, the compound has the formula:

in one embodiment, the compound has one of the following formulas:

in one embodiment, the compound has one of the following formulas:

in one embodiment, the compound has one of the following formulas:

in one embodiment, the compound has one of the following formulas:

in one embodiment, the compound has one of the following formulas:

in one embodiment, the compound has one of the following formulas:

in another embodiment, the B ring of the compounds of the invention is attached to the rest of the molecule, whereinIs thatAnd R is¹Is CH₃；

Except that when ring B isIn whichIs thatAnd R is¹Is CH₃。

In another embodiment, for compounds of the invention, Q is CH.

In another embodiment, ring a of the compounds of the present invention comprises a heterocyclyl ring or heteroaryl ring.

In another embodiment, ring A is selected from

In yet another embodiment, ring A is selected from

Wherein R is^A2Is hydrogen, C_1-4Alkyl radical, C_0-2alkyl-C_3-6Cycloalkyl radical, C_0-2Alkyl- (4-6 membered) heterocyclic group, C_2-4alkyl-OR^A2a、C_0-2alkyl-C (O) N (R)^A2a)₂、C_0-2alkyl-S (O)₂-C_1-4Alkyl or C_0-2alkyl-C (O) OC_1-4Alkyl, wherein each of said heterocyclyl groups is selected from oxetan-2-yl, azetidin-2-yl, piperidin-4-yl or 1, 1-dioxothietane-2-yl, and said R^A2Each of the radicals is optionally substituted by up to three F atoms, up to two C atoms_1-2Alkyl, up to two OR^A2bRadical, a C_0-2alkyl-N (R)^A2b)₂A radical, a C (O) R^A2bA radical, a C (O) OR^A2bA radical, a C (O) N (R)^A2b)₂Substituted by a group or a-CN group; each R^A2aIndependently is H, C_1-4Alkyl, or two R^A2aAnd the intervening nitrogen atom form a 3-6 membered heterocyclic ring selected from aziridinyl, azetidinyl, pyrrolidinyl, pyrrolidinonyl, piperidinyl, piperidinonyl, tetrahydropyridinyl, piperazinyl, or morpholinyl; each R^A2bIndependently is H or C_1-4An alkyl group; and n is 0.

In yet another embodiment, ring a is selected from

Wherein

R^A2Is hydrogen, C_1-4Alkyl radical, C_0-2alkyl-C_3-6Cycloalkyl radical, C_0-2Alkyl- (4-6 membered) heterocyclic group, C_2-4alkyl-OR^A2a、C_0-2alkyl-C (O) N (R)^A2a)₂、C_0-2alkyl-S (O)₂-C_1-4Alkyl or C_0-2alkyl-C (O) OC_1-4Alkyl, wherein each of said heterocyclyl groups is selected from oxetan-2-yl, azetidin-2-yl, piperidin-4-yl or 1, 1-dioxothietane-2-yl, and said R^A2Each of the radicals is optionally substituted by up to three F atoms, up to two C atoms_1-2Alkyl, up to two OR^A2bRadical, a C_0-2alkyl-N (R)^A2b)₂A radical, a C (O) R^A2bA radical, a C (O) OR^A2bA radical, a C (O) N (R)^A2b)₂Substituted by a group or a-CN group; each R^A2aIndependently is H, C_1-4Alkyl, or two R^A2aAnd the intervening nitrogen atom form a 3-6 membered heterocyclic ring selected from aziridinyl, azetidinyl, pyrrolidinyl, pyrrolidinonyl, piperidinyl, piperidinonyl, tetrahydropyridinyl, piperazinyl, or morpholinyl; each R^A2bIndependently is H or C_1-4An alkyl group; and n is 0.

In yet another embodiment, ring a is selected from

Wherein

R^A1Is C_1-4Alkyl radical, C_0-4alkyl-C_3-6Cycloalkyl radical, C_0-4alkyl-OR^A1a、C_0-4alkyl-C_3-6Cycloalkyl radical, C_0-4alkyl-N (R)^A1a)₂、N(R^A1a)C_2-4alkyl-N (R)^A1a)₂Wherein said R is^A1Each of the alkyl or cycloalkyl groups is optionally substituted by up to three F atoms, up to three²H atom or up to two C_0-2alkyl-OR^A1bSubstituted by groups; each R^A1aIndependently of each other is hydrogen, C_1-4Alkyl, C (O) R^A1bA group, or two R^A1aAnd the intervening nitrogen atom form a 3-6 membered heterocyclic ring selected from aziridinyl, azetidinyl, pyrrolidinyl, pyrrolidinonyl, piperidinyl, piperidinonyl, tetrahydropyridinyl, piperazinyl or morpholinyl, wherein R is^A1aEach of said alkyl or heterocyclyl groups of (a) is optionally substituted by up to three F atoms, up to two C atoms_1-2Alkyl, up to two OR^A1bSubstituted by a group or a-CN group; each R^A1bIndependently is hydrogen or C_1-2An alkyl group; each R^A4Independently is halogen,²H、C_1-4Alkyl, N (R)^1a)₂Or OC_1-4Alkyl radical, wherein each R^A4Alkyl is optionally substituted by up to 3F atoms, up to two non-geminal OH groups or up to two OC groups_1-2Alkyl substituted, and wherein n is 0-3.

In yet another embodiment, ring a is selected from

Wherein

Each R^A4Independently of one another is halogen, C_1-4Alkyl or OC_1-4Alkyl radical, wherein each R^A4Alkyl is optionally substituted by up to 3F atoms, up to two non-geminal OH groups or up to two OC groups_1-2Alkyl substituted, and wherein n is 0-2.

In another embodiment, ring B of the compounds of the present invention comprises a heterocyclyl ring or heteroaryl ring.

In one embodiment, ring B is selected from

Wherein

R^B3Is C (O) NHC_1-4Alkyl, wherein the alkyl is optionally substituted with up to three F atoms, two non-geminal OH groups, or one OC_1-2Alkyl substitution; and is

Each R^B4Independently of each other is hydrogen,²H、F、C_1-4Alkyl or OC_1-4Alkyl radical, wherein each R^B4Alkyl is optionally substituted by up to 3F atoms, two non-geminal OH groups or one

OC_1-2Alkyl substitution.

In another embodiment, ring A is

Wherein

R^A1Is F, C_1-4Alkyl, OC_1-4Alkyl, OC_0-4alkyl-C_3-5Cycloalkyl, NH₂、NHC_1-4Alkyl, NHC_0-4alkyl-C_3-5Cycloalkyl or C_0-4Alkyl-heterocyclyl, wherein the heterocyclic ring system is selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl or morpholinyl, and each of said alkyl, cycloalkyl or heterocyclyl is optionally substituted by up to three F atoms, up to three²H atom, up to two non-geminal OH groups or up to two OC groups_1-2Alkyl substitution;

each R^A4Independently F, F,²H、OC_1-4Alkyl or NH₂(ii) a And n is 0 to 2.

In another embodiment, ring B is

Wherein

R^B3And R^B4Each of which is independently hydrogen, halogen or C_1-4Alkyl, wherein R is^B3Or R^B4Each of the alkyl groups is optionally substituted by up to 3F atoms, two non-geminal OH groups or one OC_1-2Alkyl substitution;

R^B5is hydrogen, C_1-4Alkyl, C (O) C_1-4Alkyl, C (O) OC_1-4Alkyl, C (O) NH₂、C(O)NHC_1-4Alkyl or C (O) N (C)_1-4Alkyl radical)₂Wherein said R is^B5Alkyl is optionally substituted by up to 3F atoms, up to two non-geminal OH groups or up to two OC groups_1-2Alkyl substitution; and is

R^B6Is F or C_1-2Alkyl, or two R^B6And the intervening carbon atoms form a spiro cyclopropyl ring or a spiro butyl ring.

In another aspect, the invention features a compound having the formula:

wherein

X is N, CR^A5；

R^A1Is F, C_1-4Alkyl radical, C_3-5Cycloalkyl, OC_1-4Alkyl, OC_1-4alkyl-C_3-5Cycloalkyl, NH₂、NHC_1-4Alkyl, NHC_1-4alkyl-C_3-5Cycloalkyl or C_0-4Alkyl-heterocyclyl, wherein the heterocyclic ring system is selected from oxetanyl, tetrahydrofuranyl, tetrahydropyran or morpholinyl, and each of said alkyl, cycloalkyl or heterocyclyl is optionally substituted with up to three F atoms, up to three²H atom, up to two non-geminal OH groups or up to two OC groups_1-2Alkyl substitution;

each R^A4Independently is H or²H；

R^A5Is hydrogen F, C_1-4Alkyl or OC_1-4Alkyl, wherein each of said alkyl groups is optionally substituted with up to three F atoms or up to three²H atom substitution;

R^B3is C (O) NHC_1-4Alkyl, wherein said alkyl is optionally substituted with up to three F atoms, up to three²H atom, up to two non-geminal OH groups or up to two OC groups_1-2Alkyl substitution; and is

Each R^B4Independently is hydrogen, deuterium, F or C_1-4An alkyl group.

In another aspect, the invention features a compound having the formula:

wherein

X is N, CR^A5；

R^A1Is F, C_1-4Alkyl radical, C_3-5Cycloalkyl, OC_1-4Alkyl, OC_1-4alkyl-C_3-5Cycloalkyl, NH₂、NHC_1-4Alkyl, NHC_0-4alkyl-C_3-5Cycloalkyl or C_0-4Alkyl-heterocyclyl, wherein the heterocyclic ring system is selected from oxetanyl, tetrahydrofuranyl, tetrahydropyran or morpholinyl, and each of said alkyl, cycloalkyl or heterocyclyl is optionally substituted with up to three F atoms, up to three²H atom, up to two non-geminal OH groups or up to two OC groups_1-2Alkyl substitution;

each R^A4Independently is H or²H；

R^A5Is hydrogen F, C_1-4Alkyl or OC_1-4Alkyl radicalWherein each of said alkyl groups is optionally substituted with up to three F atoms or up to three²H atom substitution;

R^B3is C (O) NHC_1-4Alkyl, wherein said alkyl is optionally substituted with up to three F atoms, up to three²H atom, up to two non-geminal OH groups or up to two OC groups_1-2Alkyl substitution; and is

Each R^B4Independently is hydrogen, deuterium, F or C_1-4An alkyl group.

In another aspect, the invention features a compound selected from the compounds listed in table 1 or table 2.

Compositions, formulations and applications of the compounds of the invention

In another embodiment, the invention provides a pharmaceutical composition comprising a compound of any of the formulae described herein and a pharmaceutically acceptable excipient. In another embodiment, the present invention provides a pharmaceutical composition comprising a compound of table 1 or table 2. In another embodiment, the composition further comprises an additional therapeutic agent.

According to another embodiment, the invention provides a composition comprising a compound of the invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant or vehicle. In one embodiment, the amount of compound in the composition of the invention is an amount effective to inhibit DNA-PK in a biological sample or in a patient to a measurable extent. In another embodiment, the amount of compound in the composition of the invention is an amount effective to inhibit DNA-PK to a measurable extent. In one embodiment, the compositions of the present invention are formulated for administration to a patient in need of such a composition. In another embodiment, the compositions of the present invention are formulated for oral administration to a patient.

The term "patient" as used herein means an animal, preferably a mammal, most preferably a human.

It will also be appreciated that certain compounds of the invention may be present in free form for use in therapy, or where appropriate, as pharmaceutically acceptable derivatives thereof. According to the present invention, pharmaceutically acceptable derivatives include, but are not limited to, pharmaceutically acceptable prodrugs, salts, esters, salts of such esters, or any other adduct or derivative that is capable of providing, directly or indirectly, a compound described further herein, or a metabolite or residue thereof, upon administration to a patient in need thereof. As used herein, the term "an inhibitively active metabolite or residue thereof" means that the metabolite or residue thereof is also an inhibitor of DNA-PK.

As used herein, the term "pharmaceutically acceptable salts" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like.

Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in detail in J.pharmaceutical Sciences (J.Med.Sci.), 66:1-19,1977, S.M. Berge et al, which is incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of the present invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or salts with amino groups formed by using other methods used in the art, e.g. ion exchange. Other pharmaceutically acceptable salts include adipates, alginates, ascorbates, aspartates, benzenesulfonates, benzoates, bisulfates, borates, butyrates, camphorates, camphorsulfonates, citrates, cyclopentanepropionates, digluconates, dodecylsulfates, ethanesulfonates, formates, fumarates, glucoheptonates, glycerophosphates, gluconates, hemisulfates, heptanoates, hexanoates, hydroiodides, 2-hydroxy-ethanesulfonates, lactobionates, lactates, laurates, lauryl sulfates, malic saltsLevulinate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate and the like. Salts derived from suitable bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N⁺(C_1-4Alkyl radical)₄And (3) salt. The present invention also contemplates the quaternization of any basic nitrogen-containing group of the compounds disclosed herein. Water or oil-soluble or dispersible products can be obtained by this quaternization. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium and the like. Additional pharmaceutically acceptable salts include the use of counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, C, as appropriate_1-8Sulfonate and arylsulfonate form non-toxic ammonium, quaternary ammonium, and amine cations.

As noted above, the pharmaceutically acceptable compositions of the present invention additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, as used herein, including any and all solvents, diluents, or other liquid vehicles, dispersing or suspending aids, surfactants, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as appropriate for the particular dosage form desired. Various carriers for formulating pharmaceutically acceptable compositions and known techniques for their preparation are disclosed in the following documents: remington, The Science and Practice of pharmacy (Remington: Science and Practice of pharmacy), 21 st edition, 2005, editions D.B. Troy, Lippincott Williams and Wilkins, Philadelphia, and Encyclopedia of pharmaceutical technology (Encyclopedia of pharmacy), J.Swarkrick and J.C. Boylan editions, 1988-1999, Marcel Dekker Press, New York (New York), The contents of each of these documents are incorporated herein by reference. The use of any conventional carrier medium is considered to be within the scope of the present invention unless it is incompatible with the compounds of the present invention, for example, by causing any undesirable biological effect or otherwise interacting in a deleterious manner with one or more of any of the other components of the pharmaceutically acceptable composition.

Some examples of substances that can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, lanolin; sugars such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered gum tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol or polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; ringer's solution; ethanol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, and coloring agents, mold release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.

The compositions of the present invention may also be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intraocular, intrahepatic, intralesional, epidural, intraspinal and intracranial injection or infusion techniques. Preferably, the composition is administered orally, intraperitoneally, or intravenously. The sterile injectable form of the compositions of the present invention may be an aqueous or oleaginous suspension. These suspensions may be formulated according to the techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1, 3-butanediol. Acceptable vehicles and solvents that may be employed are water, ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally employed as a solvent or suspending medium.

For this purpose, any bland fixed oil may be employed including synthetic mono-or diglycerides. Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oily solutions or suspensions may also contain a long chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents commonly used in the formulation of pharmaceutically acceptable dosage forms, including emulsions and suspensions. Other commonly used surfactants such as tweens, spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid or other dosage forms may also be used for formulation purposes.

The pharmaceutically acceptable compositions of the present invention may be administered orally in any orally acceptable dosage form, including but not limited to capsules, tablets, aqueous suspensions or solutions. For tablets intended for oral use, commonly used carriers include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral administration, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

Alternatively, the pharmaceutically acceptable compositions of the present invention may be administered in the form of suppositories for rectal administration. These pharmaceutical compositions can be prepared by mixing the agent with suitable non-irritating excipients which are solid at room temperature but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

The pharmaceutically acceptable compositions of the present invention may also be administered topically, especially when the target of treatment includes topical application to an area or organ that is readily accessible, including ocular, skin, or lower intestinal tract disorders. Suitable topical formulations for each of these areas or organs are readily prepared.

Topical application to the lower intestinal tract may be achieved in rectal suppository formulations (see above) or in suitable enema formulations. Topical transdermal patches may also be used.

For topical application, pharmaceutically acceptable compositions may be formulated as a suitable ointment containing the active ingredient suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid paraffin, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutically acceptable compositions may be formulated in a suitable lotion or cream containing the active ingredient suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

For ophthalmic use, the pharmaceutically acceptable compositions may be formulated, for example, as micronized suspensions in isotonic, pH adjusted sterile saline or other aqueous solutions, or preferably as solutions in isotonic, pH adjusted sterile saline or other aqueous solutions, with or without preservatives such as benzalkonium chloride. Alternatively, for ophthalmic use, the pharmaceutically acceptable composition may be formulated in an ointment such as petrolatum. The pharmaceutically acceptable compositions of the present invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and may be prepared as solutions in saline using benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.

Most preferably, the pharmaceutically acceptable compositions of the present invention are formulated for oral administration.

Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1, 3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. In addition to inert diluents, oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Injections may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents, for example, as sterile injectable aqueous or oily suspensions. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1, 3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, U.S. p. ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono-or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

To prolong the effect of the compounds of the present invention, it is often desirable to slow the absorption of the compounds from subcutaneous or intramuscular injection. This can be achieved by using a liquid suspension of crystalline or amorphous material which is poorly water soluble. The rate of absorption of the compound then depends on its rate of dissolution, which in turn may depend on crystal size and crystal form. Alternatively, the compound is dissolved or suspended in an oil vehicle to achieve delayed absorption of the parenterally administered compound form. Injectable depot forms are made by forming a microencapsulated matrix of the compound in a biodegradable polymer such as polylactide-polyglycolide. Depending on the ratio of compound to polymer and the nature of the particular polymer employed, the rate of release of the compound can be controlled. Examples of other biodegradable polymers include poly (orthoesters) and poly (anhydrides). Depot injectable formulations can also be prepared by entrapping the compound in liposomes or microemulsions which are compatible with body tissues.

Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of the invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and thus melt in the rectum or vaginal cavity and release the active compound.

Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is mixed with at least one inert pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. Solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and may also have a composition such that they release the active ingredient only, or preferentially, in a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymers and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The active compound may also be in microencapsulated form with one or more of the above-mentioned excipients. Solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells such as enteric coatings, controlled release coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms, the active compound may be mixed with at least one inert diluent such as sucrose, lactose or starch. As is conventional, such dosage forms may also contain additional substances other than inert diluents, for example, tableting lubricants and other tableting aids such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and may also have a composition such that they release the active ingredient only, or preferentially, in a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymers and waxes.

Topical or transdermal administration forms of the compounds of the present invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active ingredient is mixed under sterile conditions with a pharmaceutically acceptable carrier and any required preservatives or buffers which may be required. Ophthalmic formulations, ear drops and eye drops are also contemplated within the scope of the present invention. In addition, the present invention contemplates the use of transdermal patches, which have the added advantage of allowing controlled delivery of the compound to the body. Such dosage forms may be prepared by dissolving or dispensing the compound in the appropriate medium. Absorption enhancers may also be used to increase the flux of the compound across the skin. The rate can be controlled by providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

The compounds of the present invention are preferably formulated in unit dosage form for ease of administration and to maintain uniform dosage. The expression "unit dosage form" as used herein refers to a physically discrete unit of medicament suitable for the patient to be treated. It will be understood, however, that the total daily amount of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific effective dosage level for any particular patient or organism will depend upon a variety of factors including: the condition treated and the severity of the condition; the activity of the particular compound used; the specific composition used; the age, weight, general health, sex, and diet of the patient; the time of administration, route of administration, and rate of excretion of the particular compound used; the duration of treatment; drugs used in combination or concomitantly with the specific compound employed, and similar factors well known in the medical arts.

The amount of a compound of the present invention that can be combined with a carrier material to produce a single dosage form of the composition will vary depending upon the host treated, the particular mode of administration. Preferably, the compositions should be formulated so that a dose of between 0.01mg and 100mg of inhibitor per kilogram of body weight per day can be administered to a patient receiving these compositions.

Depending on the particular proliferative disorder or cancer to be treated, additional therapeutic agents typically administered to treat or prevent the disorder may also be present in the compositions of the invention. As used herein, an additional therapeutic agent that is typically administered to treat or prevent a particular proliferative disorder or cancer is considered "appropriate for the disease or disorder being treated. Examples of additional therapeutic agents are provided below.

The amount of additional therapeutic agent present in the compositions of the present invention will not exceed that normally administered in compositions containing the therapeutic agent as the only active agent. Preferably, the amount of additional therapeutic agent in the disclosed compositions will be in the range of about 50% to 100% of the amount typically present in compositions comprising the agent as the sole therapeutically active agent.

Use of the Compounds and compositions of the invention

In one embodiment, the invention provides a method of increasing the sensitivity of a cell to an agent that induces DNA damage, the method comprising the step of contacting the cell with one or more DNA-PK inhibitors of formula I or subformulae thereof (e.g., formula I-A-1, I-A-2, … to I-A-51, I-B-1, I-B-2, … to I-B-42) or formula II or formula III.

The present invention also provides a method of enhancing a therapeutic regimen for treating cancer comprising the step of administering to a subject in need thereof a therapeutically effective amount of a DNA-PK inhibitor of formula I, formula II, formula III or subformulae thereof. In one embodiment, the treatment regimen for treating cancer comprises radiation therapy. The compounds of the invention are useful in situations where radiation therapy is indicated to enhance the therapeutic benefit of such treatment. In addition, radiation therapy is often indicated as an adjunct to surgery in the treatment of cancer. In the context of adjuvant therapy, the goal of radiotherapy is to reduce the risk of recurrence and increase disease-free survival when the primary tumor has been managed. For example, adjuvant radiation therapy is indicated for cancers, including but not limited to breast cancer, colorectal cancer, gastro-esophageal cancer, fibrosarcoma, glioblastoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, melanoma, lung cancer, pancreatic cancer, and prostate cancer, as described below.

The invention may also be practiced by including another anti-cancer chemotherapeutic agent with a compound of the invention in a therapeutic regimen for the treatment of cancer, with or without radiation therapy. The combination of the DNA-PK inhibitor compounds of the invention with such other agents may enhance the chemotherapy regimen. For example, the inhibitor compounds of the present invention may be administered with etoposide or bleomycin, an agent known to cause DNA strand breaks.

The invention also relates to the use of compounds of formula I, formula II, formula III or subformulae thereof for increasing the radiosensitivity of tumor cells. Preferred compounds are those described for the pharmaceutical compositions of the present invention. As used herein, a compound that increases radiosensitivity of a cell is defined as a molecule, preferably a low molecular weight molecule, administered to an animal in a therapeutically effective amount to increase the sensitivity of the cell to electromagnetic radiation and/or to facilitate treatment of a disease treatable with electromagnetic radiation (e.g., X-rays). Diseases that can be treated with electromagnetic radiation include neoplastic diseases, benign and malignant tumors, and cancerous cells.

The invention also provides a method of treating cancer in an animal comprising administering to the animal a therapeutically effective amount of a DNA-PK inhibitor, e.g. a compound of the invention. The invention also relates to methods of inhibiting cancer cell growth (including processes of cell proliferation, infiltration, and metastasis) in biological systems. The methods comprise using the compounds of the invention as inhibitors of cancer cell growth. Preferably, the method is employed to inhibit or reduce the incidence of cancer cell growth, infiltration, metastasis or tumor in a living animal such as a mammal. The methods of the invention are also readily applicable to assay systems, such as measuring cancer cell growth and its properties and identifying compounds that affect cancer cell growth.

Tumors or neoplasms include tissue cell growth in which the multiplication of cells is uncontrolled and progressive. Some of these growths are benign, but others are called "malignant" and can lead to the death of the organism. Malignant neoplasms or "cancers" are distinguished from benign growths in that, in addition to exhibiting aggressive cellular proliferation, they can invade surrounding tissues and metastasize. In addition, malignant neoplasms are characterized in that they exhibit a greater degree of loss of differentiation (higher "dedifferentiation") and their organization relative to each other and their surrounding tissues. This property is also referred to as "anaplasia".

Neoplasms that can be treated by the present invention also include solid tumors, i.e., carcinomas and sarcomas. Cancer includes those malignant neoplasms derived from epithelial cells that infiltrate (infiltrate) the surrounding tissue and produce metastases. Adenocarcinomas are carcinomas derived from glandular tissue or from tissues that form recognizable glandular structures. Another broad class of cancers includes sarcomas, which are tumors in which cells are embedded in a fibrous or homogeneous mass, such as embryonic connective tissue. The invention also enables the treatment of cancers of the bone marrow or lymphatic system, including leukemias, lymphomas, and other cancers that do not normally exist as tumor masses but are distributed in the vascular or lymphatic reticulum system.

DNA-PK activity can be associated with the growth of various forms of cancer, e.g., in adult and pediatric oncology, as well as cancers/tumors as follows: solid/malignant tumors, myxoid and round cell carcinomas, locally advanced tumors, metastatic cancers, human soft tissue sarcomas (including Ewing's sarcoma), cancer metastases (including lymphatic metastases), squamous cell cancers (especially head and neck squamous cell carcinomas, esophageal squamous cell carcinomas), oral cancers, blood cell malignancies (including multiple myeloma), leukemias (including acute lymphocytic leukemia, acute non-lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia), effusion lymphomas (coelomic-based lymphomas), thymic lymphoma, lung cancers (including small cell carcinoma), cutaneous T cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, cancers of the adrenal cortex, ACTH-producing tumors, non-small cell cancers, Breast cancer (including small cell and ductal carcinoma), gastrointestinal cancer (including gastric, colon, colorectal cancer), polyps associated with colorectal neoplasia, pancreatic cancer, liver cancer, urinary system cancer (including bladder cancer, including primary superficial bladder tumor, invasive transitional cell cancer of the bladder, and muscle-invasive bladder cancer), prostate cancer, malignancy of the female reproductive tract (including ovarian cancer, primary peritoneal epithelial cell tumor, cervical cancer, endometrial cancer, vaginal cancer, vulval cancer, uterine cancer, and follicular solid cancer), malignancy of the male reproductive tract (including testicular cancer and penile cancer), kidney cancer (including renal cell cancer), brain cancer (including endogenous brain tumor, neuroblastoma, astrocytoma, glioma, metastatic tumor cell infiltration in the central nervous system), bone cancer (including bone tumor and osteosarcoma), and colon cancer, Skin cancer (including malignant melanoma, progressive tumors of human skin keratinocytes, squamous cell carcinoma), thyroid cancer, retinoblastoma, neuroblastoma, peritoneal leakage, malignant pleural leakage, mesothelioma, Wilms 'tumor, gallbladder cancer, trophoblastic tumors, hemangiopericyte tumors, and Kaposi's sarcoma. The present invention encompasses methods of enhancing the treatment of these and other forms of cancer.

The present invention provides methods of inhibiting DNA-PK activity in a biological sample, comprising contacting the biological sample with a compound or composition of the invention. The term "biological sample" as used herein means a sample that is outside of a living organism and includes, but is not limited to, cell cultures or extracts thereof; biopsy material obtained from a mammal or an extract thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof. Inhibition of kinase activity, particularly DNA-PK activity, in biological samples can be used for a variety of purposes known to those skilled in the art. Examples include, but are not limited to, inhibition of DNA-PK in a bioassay. In one embodiment, the method of inhibiting DNA-PK activity in a biological sample is limited to a non-therapeutic method.

Preparation of the Compounds of the invention

All abbreviations, symbols and conventions used herein are consistent with those used in the contemporary scientific literature. See, e.g., Janet S.Dodd, The ACS Style Guide, A Manual for Authors and Editors (ACS Format Guide: Authors and Editors), 2 nd edition, Washington D.C. (Washington, D.C.): american chemical society (American chemical society), 1997. The following definitions describe the terms and abbreviations used herein:

BPin boronic acid pinacol ester

Saturated NaCl solution in brine

DCM dichloromethane

DIEA diisopropylethylamine

DMA dimethyl acetamide

DME dimethoxyethane

DMF dimethyl formamide

DMSO dimethyl sulfoxide

DTT dithiothreitol

EtDuPhos (2R,5R) -1- [2- [ (2R,5R) -2, 5-diethylphospholan-1-yl ] phenyl ] -2, 5-diethylphospholane

ESMS electrospray mass spectrometry

Et₂O Ether

EtOAc ethyl acetate

EtOH ethanol

HATU O- (7-azabenzotriazol-1-yl) -N, N, N ', N' -tetramethyluronium hexafluorophosphate

HEPES 4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid

HPLC high performance liquid chromatography

IPA isopropyl alcohol

LAH lithium aluminum hydride

LC-MS liquid chromatography-mass spectrometry combined method

LDA lithium diisopropylethyl amide

Me methyl group

MeOH methanol

MTBE methyl tert-butyl ether

NMP N-methylpyrrolidine

Pd(dppf)Cl₂1,1' bis (diphenylphosphino) -ferrocene palladium dichloride

Ph phenyl

RT or RT Room temperature

SFC supercritical fluid chromatography

SPhos 2-dicyclohexylphosphine-2 ',6' -dimethoxybiphenyl

TBAI tetrabutylammonium iodide

TBME Tert-butyl methyl Ether

tBu tert-butyl

THF tetrahydrofuran

TEA Triethylamine

TMEDA Tetramethylethylenediamine

VPhos [3- (2-dicyclohexylphosphinophenyl) -2, 4-dimethoxy-phenyl ] sulfonic acid sodium salt

General synthetic procedure

In general, the compounds of the invention may be prepared by the methods described herein or by other methods known to those skilled in the art.

Example 1. General preparation of Compounds of formula I

Compounds of formula I may be prepared as outlined in scheme 1-method a below. Thus, as shown in step 1-i of scheme 1,4, 6-dichloropyrimidine is reacted with an amine of formula a in the presence of a tertiary amine base at elevated temperature to produce a compound of formula B. As shown in steps 1-ii of scheme 1, the compound of formula B is reacted with a suitable boronic acid or boronic ester of formula C in the presence of a suitable palladium catalyst to produce the compound of formula I. The procedure for the preparation of Boronic esters or Boronic Acids from aryl or heteroaryl halides is described in Boronic Acids (boric acid), ISBN:3-527-30991-8, Wiley-VCH,2005 (edited by Dennis G.Hall). In one example, the halogen is bromine and the boronic ester is prepared by reacting an aryl or heteroaryl bromide with 4,4,5, 5-tetramethyl-2- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1,3, 2-dioxaborolan. In a subsequent coupling reaction, the boronic ester or boronic acid thus formed may be reacted with a halopyrimidine in the presence of a palladium catalyst such as 1,1' bis (diphenylphosphino) -ferrocene palladium dichloride pi dichloromethane [ Pd (dppf) Cl₂]Then the reaction is carried out.

Alternatively, the order of coupling of the compounds of formula a and C with 4, 6-dichloropyrimidine can be reversed as shown in scheme 1-method B to produce the compounds of formula I of the invention.

The compounds of formula I can also be prepared by forming a carbon-carbon bond between the carbon atom of the aromatic or heteroaromatic B-ring moiety and the unsaturated 2-carbon of N-allylpyrimidin-4-amine using suzuki borate type coupling. In one example, as shown in scheme 1-method C, a compound of formula D is reacted with an allylamine borate ester of formula E to produce a compound of formula F. Subsequent reaction of the boronic ester with an aromatic or heteroaromatic B ring halide of formula G provides a compound of formula H, the double bond of which can be reduced to form a compound of formula I.

Alternatively, as shown in scheme 1-method D, the carbon-carbon bond between the aromatic or heteroaromatic B ring and the remainder of the molecule in the compound of formula I is formed by reacting a vinyl halide of formula K with a B-ring borate of formula L. As before, the double bond of the resulting compound of formula H may be reduced to form the compound of formula I.

As previously mentioned, aryl or heteroaryl halides or vinyl halides can be prepared by reacting an aryl or heteroaryl halide with 4,4,5, 5-tetramethyl-2- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1,3, 2-dioxaborolan in the presence of a palladium catalyst such as 1,1' bis (diphenylphosphine) -ferrocene dichloropalladium dichloride pi. dichloromethane [ Pd (dppf) Cl₂]To prepare a boronic ester or acid intermediate. For example, to prepare the cyclic a boronic ester intermediate of formula O, the procedure outlined in example 2 may be followed.

Example 2. General preparation of Ring A intermediates of formula O

As shown in scheme 2, step 2-i, to a compound of formula M (1 equivalent) and K at room temperature₂CO₃(3 equiv.) solution in DMF (0.3M) alkyl bromide (2 equiv.) was added. The reaction mixture was then stirred at 80 ℃ for 5 hours. The reaction was cooled to room temperature and filtered through a pad of celite. The resulting filter cake was washed with EtOAc. Adding H to the filtrate₂O and the two phases are separated. The aqueous phase was extracted with EtOAc and the organic phase was washed with brine. Combining the organic phasesWith Na₂SO₄Dried and evaporated. The residue was purified by medium pressure silica gel chromatography (0 → 100% EtOAc in hexanes) to afford intermediate N.

As shown in step 2-ii of scheme 2, 5-bromo-pyrazolo [3,4-b of formula N]Solutions of pyridine (1 equivalent), bis-pinacolborane (1.15 equivalents), KOAc (3 equivalents) in 2-methyl-THF (0.3M) were treated with N₂The gas stream was degassed for 20 minutes. Then, Pd (dppf) Cl₂(0.05 eq) was added to the reaction mixture. The resulting solution was heated in a sealed tube at 120 ℃ for 3 hours in an oil bath. The solution was cooled to room temperature and filteredA pad. The filtrate was evaporated to give the resulting compound of formula O. In many cases, these compounds can be used subsequently without any additional purification.

The following compound can be prepared following the procedure of example 2.

2- (5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-pyrazolo [3, 4-b)]Pyridin-1-yl) ethanol: ESMS (M + H) ═ 289.43;¹H NMR(400MHz,CDCl₃)8.79(d, J ═ 0.7Hz,1H),8.48(d, J ═ 0.4Hz,1H),7.97(s,1H),4.63(t, J ═ 4.6Hz,2H),4.45(s,1H),4.05(t, J ═ 4.6Hz,2H) and 1.30(s,12H)

1- (2-methoxyethyl) -5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-pyrazolo [3,4-b]Pyridine: ESMS (M + H) ═ 303.16;¹H NMR(400MHz,CDCl₃)8.81(d, J ═ 1.2Hz,1H),8.44(d, J ═ 1.2Hz,1H),7.97(s,1H),4.67(t, J ═ 5.6Hz,2H),3.82(t, J ═ 5.6Hz,2H),3.25(s,3H) and 1.30(s,12H)

1- (cyclopropylmethyl) -5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-pyrazolo [3,4-b]Pyridine: ESMS (M + H) ═ 301.14;¹H NMR(400MHz,CDCl₃)8.79(d, J ═ 1.0Hz,1H),8.44(d, J ═ 1.0Hz,1H),7.96(s,1H),4.35(d, J ═ 7.1Hz,2H),1.35(s,12H) and 0.49-0.39(m,5H)

1- (thietane-1, 1-dioxide) -5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-pyrazolo [3,4-b ] pyridine: ESMS (M + H) ═ 350.37

N-ethyl-2- (5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-pyrazolo [3,4-b ] pyridin-1-yl) acetamide: ESMS (M + H) ═ 331.66

1- (2- (5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-pyrazolo [3,4-b ] pyridin-1-yl) ethyl) pyrrolidin-2-one: ESMS (M + H) ═ 358.12

1- (Oxetan-3-yl) -5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-pyrazolo [3,4-b]Pyridine: ESMS (M + H))＝302.16；¹H NMR(400MHz,CDCl₃)8.80(d,J＝10.8Hz,1H),8.45(s,1H),8.06(s,1H),6.19(p,J＝7.2Hz,1H),5.25(t,J＝6.5Hz,2H),5.08–5.03(m,2H),1.30(s,12H)

1-methyl-5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-pyrazolo [3,4-b]Pyridine: ESMS (boric acid, M + H) ═ 178.23;¹H NMR(400MHz,CDCl₃) d 8.93(d, J ═ 1.2Hz,1H),8.45(d, J ═ 1.1Hz,1H),7.87(s,1H),4.18(s,3H) and 1.29(s,12H)

2-methyl-2- (5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-pyrazolo [3, 4-b)]Pyridin-1-yl) propionic acid ethyl ester: ESMS (M + H) ═ 360.29;¹H NMR(400MHz,CDCl3)8.94(s,1H),8.47(s,1H),8.04(s,1H),4.16–4.05(m,2H),1.95(s,6H),1.30(s,12H),1.13–1.05(m,3H)

2- (5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-pyrazolo [3, 4-b)]Pyridin-1-yl) acetic acid methyl ester: ESMS (M + H) ═ 317.2;¹H NMR(400MHz,CDCl₃)8.90(d,J＝1.1Hz,1H),8.56(t,J＝3.9Hz,1H),8.11(d,J＝7.7Hz,1H),5.36(s,2H),3.76(s,3H),1.38(s,12H)

1- (Oxetan-3-yl) -5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-pyrrolo [2,3-b ]]Pyridine: ESMS (M + H) 301.4;¹H NMR(400MHz,CDCl3)8.72–8.52(m,1H),8.41–8.28(m,1H),7.71(d,J＝3.4Hz,1H),6.64(dd,J＝24.9,3.5Hz,1H),6.18(dd,J＝13.6,6.6Hz,1H),5.30–5.02(m,4H),1.28(s,12H)

2- (5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-pyrrolo [2,3-b ] pyridin-1-yl) ethanol: ESMS (M + H) ═ 289.32

1- (cyclopropylmethyl) -5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-pyrrolo [2,3-b ] pyridine: ESMS (M + H) ═ 299.38

1-methyl-5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-pyrrolo [2,3-b ] amine]Pyridine: ESMS (M + H) ═ 260.14;¹H NMR(400MHz,CDCl₃) d 8.63(d, J ═ 1.0Hz,1H),8.28(d, J ═ 1.0Hz,1H),7.08(d, J ═ 3.4Hz,1H),6.38(d, J ═ 3.4Hz,1H),3.83(s,3H) and 1.30(s,12H)

2- (5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-indazol-1-yl) ethanol: ESMS (M + H) ═ 289.33

1- (cyclopropylmethyl) -5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-indazole: ESMS (M + H) ═ 298.02

2- (3-methyl-5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-indazol-1-yl) ethanol: ESMS (M + H) ═ 302.22;¹H NMR(400MHz,CDCl₃)8.18–8.04(m,1H),7.70(dd,J＝18.8,8.1Hz,1H),7.30(dd,J＝20.1,8.5Hz,1H),4.36(dt,J＝9.4,5.1Hz,2H),4.22–3.96(m,2H),2.58–2.47(m,3H),1.20(t,J＝2.0Hz,12H)

2- (4-methyl-5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-indazol-1-yl) ethanol: ESMS (M + H) ═ 302.22;¹H NMR(400MHz,CDCl₃)8.07–7.93(m,1H),7.71(t,J＝9.9Hz,1H),7.15(d,J＝8.6Hz,1H),4.50–4.34(m,2H),4.16–3.98(m,2H),2.80–2.67(m,3H),1.20(s,12H)

1- (oxetan-3-yl) -5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-indazole: ESMS (M + H) ═ 301.34

3-methyl-1- (oxetan-3-yl) -5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-indazole: ESMS (M + H) ═ 315.57;¹H NMR(400MHz,CDCl₃)8.23(d,J＝8.2Hz,1H),7.82(d,J＝8.5Hz,1H),7.49–7.41(m,1H),5.74(p,J＝7.1Hz,1H),5.31(t,J＝6.5Hz,2H),5.12(t,J＝7.2Hz,2H),2.63(d,J＝5.1Hz,3H),1.40(s,12H)

4-methyl-1- (oxetan-3-yl) -5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-indazole: ESMS (M + H) ═ 315.57;¹H NMR(400MHz,CDCl₃)8.06(d,J＝21.0Hz,1H),7.72(d,J＝8.5Hz,1H),7.32–7.20(m,1H),5.76–5.63(m,1H),5.24(dd,J＝12.3,5.7Hz,2H),5.05(t,J＝7.3Hz,2H),2.76(s,3H),1.30(s,12H)

6-methyl-1- (oxetan-3-yl) -5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1H-indazole:

ESMS(M+H)＝315.57；¹H NMR(400MHz,CDCl₃)8.17(s,1H),7.94(s,1H),7.19(s,1H),5.76–5.59(m,1H),5.29–5.18(m,2H),5.12–4.99(m,2H),2.61(s,3H),1.29(s,12H)

example 3. N- (2- (3, 3-dimethyl-2, 3-dihydrobenzofuran-7-yl) ethyl) -6- (6- (4-methylpiperazine- Preparation of 1-yl) pyridin-3-yl) pyrimidin-4-amine (Compound 68)

As shown in scheme 3, step 3-i, 3-bromo-2-methyl-prop-1-ene (12.8g,9.61mL,95.37mmol) was added to a solution of 2-bromophenol (15g,86.7mmol) in DMF 180mL) at 0 deg.C, followed by K₂CO₃(23.96g,173.4mmol) and TBAI (384mg,1.04 mmol). The reaction mixture was then stirred at room temperature for 24 hours and H₂O (90mL) quench. The aqueous phase was extracted with EtOAc and the organic phase was taken over Na₂SO₄And (5) drying. The volatiles were removed under reduced pressure to give 1-bromo-2- ((2-methylallyl) oxy) benzene (compound 2001, 19.12g, 97% yield, colorless liquid):¹H NMR(400MHz,CDCl₃)7.46(dd, J ═ 1.5,7.8Hz,1H),7.18-7.13(m,1H),6.81-6.73(m,2H),5.09(s,1H),4.93(t, J ═ 1.1Hz,1H),4.42(s,2H) and 1.78(s,3H) ppm. This material was used as such in the subsequent reaction.

As shown in step 3-ii of scheme 3, with N₂A gas stream degassed a solution of compound 2001(13.8g,60.7mmol), NaOAc (12.46g,151.9mmol), tetraethylammonium chloride hydrate (13.4g,72.9mmol) and sodium formate (4.95g,72.9mmol) in DMF (140mL) for 30 min. Addition of Pd (OAc)₂(682.1mg,3.04mmol) and the mixture was heated to 90 ℃ for 4 h. The reaction mixture was cooled to room temperature and Et₂Dilution with O (50 mL). The resulting solution was filtered through celite and washed with H₂The filtrate was washed with brine. The organic phase is treated with Na₂SO₄Dried, concentrated under reduced pressure, and purified by medium pressure chromatography on silica gel (0 to 20% EtOAc in hexanes) to give 3, 3-dimethyl-2, 3-dihydrobenzofuran (compound 2002, 3.86g, 43% yield) as a colorless oil:¹H NMR(400MHz,CDCl₃)7.03(d, J ═ 7.6Hz,2H),6.81(t, J ═ 7.4Hz,1H),6.72(d, J ═ 7.8Hz,1H),4.15(d, J ═ 0.7Hz,2H) and 1.27(s,6H) ppm.

As shown in step 3-ii of scheme 3, TMEDA (3.93g,5.11mL,33.8mmol) in Et at-78 deg.C₂To a solution in O (60mL) was added sec-butyllithium (22.3mL,1.4M,31.2 mmol). After 10 min at-78 ℃ Et was added dropwise over 15 min₂3, 3-dimethyl-2H-benzofuran (compound 2002, 3.86g, 26.0mmol) in O (60 mL). After 10 minutes, the mixture was stirred at 0 ℃ for 30 minutes. The solution was then cooled to-78 ℃ and DMF (4.76g,5.04mL,65.1mmol) was added dropwise. The reaction mixture was stirred at-78 ℃ for 10 minutes and then allowed to warm to 0 ℃ over 2 hours. The reaction was quenched with 1N HCl (20mL) and hexanes/Et₂Dilution with O (1:1,50 mL). Adding Na to the organic matter₂SO₄Drying and removing volatiles under reduced pressureThe material was purified to give 3, 3-dimethyl-2, 3-dihydrobenzofuran-7-carbaldehyde (compound 2003, 4.1g, 89% yield):¹H NMR(400MHz,CDCl₃)10.14(s,1H),7.53(dd, J ═ 1.3,7.8Hz,1H),7.25(dd, J ═ 1.3,7.2Hz,1H),6.90(t, J ═ 7.5Hz,1H),4.34(s,2H) and 1.30(s,6H) ppm; ESMS (M + H) ═ 177.25.

As shown in scheme 3, step 3-iv, nitromethane (519.5mg, 461.0. mu.L, 8.511mmol) and ammonium acetate (546.7mg,7.092mmol) were added at room temperature to a solution of 3, 3-dimethyl-2H-benzofuran-7-carbaldehyde (0.5g,2.837mmol) in AcOH (11.1 mL). The reaction mixture was then heated at 110 ℃ for 2 hours. The reaction mixture was then cooled and the volatiles were removed under reduced pressure. The residue was dissolved in DCM and washed with H₂The organic phase was washed with O and brine, Na₂SO₄Dried, concentrated under reduced pressure, and purified by medium pressure chromatography on silica gel (0 to 75% EtOAc in hexanes) to give (E) -3, 3-dimethyl-7- (2-nitrovinyl) -2, 3-dihydrobenzofuran (compound 2004, 160mg, 34% yield) as a yellow solid:¹HNMR(400MHz,CDCl₃)7.91(q, J ═ 13.4Hz,2H),7.14(t, J ═ 7.1Hz,2H),6.88(t, J ═ 7.5Hz,1H),4.34(s,2H) and 1.30(s,6H) ppm; ESMS (M + H) ═ 220.02.

As shown in scheme 3, steps 3-v, to LiAlH at room temperature₄To the solution of (4.01mL,1M/THF,4.01mmol) was added (E) -3, 3-dimethyl-7- (2-nitrovinyl) -2, 3-dihydrobenzofuran (160mg,0.72mmol) in THF (14.0 mL). The yellow solution was stirred at room temperature for 15 hours. The reaction was quenched very slowly with water (15mL) and Et₂O and EtOAc extraction. Adding Na to the organic matter₂SO₄Dried and concentrated under reduced pressure to give 2- (3, 3-dimethyl-2, 3-dihydrobenzofuran-7-yl) ethylamine (compound 2005, 139mg, 99% yield):¹H NMR(400MHz,CDCl₃)6.90(dd, J ═ 6.2,6.9Hz,2H),6.79-6.71(m,1H),4.15(s,2H),2.88(t, J ═ 6.9Hz,2H),2.65(t, J ═ 6.9Hz,2H) and 1.26(s,6H) ppm; ESMS (M + H) ═ 192.07.

As shown in scheme 3, steps 3-vi, 4, 6-dichloropyrimidine (111.6mg,0.726mmol), 2- (3, 3-dimethyl-2H-benzofuran-7-yl)Ethylamine (139mg,0.726mmol), Na₂CO₃A solution (231.1mg,2.180mmol) in i-PrOH (5.56mL) was sealed in a microwave type tube and heated in an oil bath at 90 ℃ for 18 hours. The reaction mixture was filtered through a pad of celite, the volatiles were removed under reduced pressure, and the residue was purified by medium pressure chromatography on silica gel (0 to 100% EtOAc in hexanes) to give 6-chloro-N- (2- (3, 3-dimethyl-2, 3-dihydrobenzofuran-7-yl) ethyl) pyrimidin-4-amine (compound 2006) as a colorless oil:¹H NMR(400MHz,CDCl₃)8.24(s,1H),6.94(d, J ═ 7.3Hz,1H),6.88(d, J ═ 7.4Hz,1H),6.78(t, J ═ 7.4Hz,1H),6.25(s,1H),4.20(d, J ═ 5.9Hz,2H),4.05(d, J ═ 7.1Hz, H),3.47(s,2H),2.83(t, J ═ 6.6Hz,2H),1.50(s,2H) and 1.27(s,6H) ppm; ESMS (M + H) ═ 304.06.

As shown in scheme 3, steps 3-vii, with N₂The gas stream was purified by mixing-chloro-N- (2- (3, 3-dimethyl-2, 3-dihydrobenzofuran-7-yl) ethyl) pyrimidin-4-amine (60mg,0.197mmol), 1-methyl-4- [5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -2-pyridinyl]Piperazine (71.86mg,0.237mmol), Na₂CO₃(296.2 μ L,2M,0.592mmol) and [3- (2-dicyclohexylphosphinophenyl) -2, 4-dimethoxy-phenyl]A solution of sodium sulfonate (VPhos,8.1mg,0.0158mmol) in i-PrOH (1.6mL) was degassed for 30 minutes. Addition of Pd (OAc)₂(0.88mg,0.0039mmol) and the solution was heated to 90 ℃ for 2 h. The solution was concentrated under reduced pressure and purified by medium pressure chromatography on silica gel (0 to 100% MeOH in hexanes) (10%) to give N- (2- (3, 3-dimethyl-2, 3-dihydrobenzofuran-7-yl) ethyl) -6- (6- (4-methylpiperazin-1-yl) pyridin-3-yl) pyrimidin-4-amine (compound 68, 32.4mg, 36%) as a white solid:¹HNMR(400MHz,CDCl₃)8.69(s,1H),8.49(s,1H),8.07(d, J ═ 8.1Hz,1H),6.94-6.90(m,2H),6.77(t, J ═ 7.3Hz,1H),6.62(d, J ═ 8.9Hz,1H),6.55(s,1H),5.30(s,1H),4.20(s,2H),3.60(s,6H),2.86(t, J ═ 6.4Hz,2H),2.45(s,4H),2.28(s,3H) and 1.27(s,6H) ppm; ESMS (M + H) ═ 445.09.

Example 4. (S) -N- (2- (2-methoxyphenyl) propyl) -6- (6- (4-methylpiperazin-1-yl) pyridin-3-yl) pyrimidine Preparation of pyridin-4-amine (Compound 32)

As shown in step 4-i of scheme 4, at-78 ℃ in N₂Next, to a solution of diisopropylamine (6.70g,9.28mL,66.2mmol) in THF (60mL) was added n-butyllithium (33.1mL of a 2.0M cyclohexane solution, 66.2mmol), and the solution was stirred for 40 minutes. A solution of 2- (2-methoxyphenyl) acetic acid (5.00g,30.1mmol) in THF (30mL) was added dropwise, and the reaction was allowed to warm to room temperature over one hour. The reaction was then cooled to-78 ℃ and methyl iodide (4.27g,1.87mL,30.1mmol) was added to the reaction in one portion. The reaction was warmed to room temperature for 18 hours, 15mL of water was added, the organics were collected and the volatiles were removed under reduced pressure. The residue was acidified with 1N HCl and Et₂The crude product was O (3X) extracted. The combined organics were washed with MgSO₄Drying, filtration, concentration under reduced pressure, and purification of the residue by medium pressure chromatography on silica gel (25 to 50% EtOAc in hexanes) afforded 2- (2-methoxyphenyl) propionic acid as a white solid (compound 2008, 4.86g, 85% yield):¹HNMR(CDCl₃)7.31–7.21(m,2H),7.01–6.84(m,2H),4.09(q,J＝7.2Hz,1H),3.84(s,3H),1.49(d,J＝7.2Hz,3H)。

to a solution of 2- (2-methoxyphenyl) propionic acid (1.50g,7.91mmol) in THF (20mL) at 0 deg.C was added lithium aluminum hydride (31.6mL of a 0.5M solution, 15.8mmol) as shown in scheme 4, step 4-ii, the reaction was warmed to room temperature and stirred for 3.5 hours. 0.7mL of water, 0.7mL of 1M NaOH, 1.9mL of water, and MgSO (MgSO) as a separate water were added in this order₄Thereafter, the reaction mixture was filtered through celite and concentrated under reduced pressure to give a clear, colorless liquid of 2- (2-methoxyphenyl) -1-propanol (compound 2009, 1.41g, 96% yield):¹H NMR(CDCl₃)7.27–7.20(m,2H),7.03–6.87(m,2H),3.85(s,3H),3.67(m,2H),3.54–3.42(m,1H),1.54(t,J＝6.1Hz,1H),1.29(d,J＝7.1Hz,3H)。

as shown in scheme 4, step 4-iii, 2- (2-methoxyphenyl) -1-propanol (1.31g,7.08mmol), phthalimide (1.0)9g,7.44mmol) and PPh₃The mixture of resin (3.43g,10.6mmol) was stirred at room temperature for 15 minutes to allow the resin to swell. Diisopropyl azodicarboxylate (2.29g,2.24mL,10.6mmol) was added and the reaction was stirred for 18 h. The reaction mixture was filtered through celite, which was then washed with EtOAc and DCM. The filtrate was concentrated under reduced pressure and purified by medium pressure chromatography on silica gel (10 to 20% EtOAc in hexanes) to give a clear, colorless oil of 2- (2- (2-methoxyphenyl) propyl) isoindoline-1, 3-dione (compound 2010, 2.15g, quantitative yield):¹H NMR(CDCl₃)7.81(dd,J＝5.5,3.0Hz,2H),7.69(dd,J＝5.5,3.0Hz,2H),7.34–7.24(m,1H),7.19(ddd,J＝8.1,7.5,1.7Hz,1H),6.94(td,J＝7.5,1.1Hz,1H),6.76(dd,J＝8.2,0.9Hz,1H),4.03–3.69(m,3H),3.66(s,3H),1.32(d,J＝6.8Hz,3H)。

to a stirred solution of 2- (2- (2-methoxyphenyl) propyl) isoindoline-1, 3-dione (363mg,1.23mmol) in MeOH (4.0mL) was added hydrazine (39.4mg, 38.6. mu.L, 1.23mmol) and the reaction was stirred for 18 hours as shown in scheme 4, step 4-iv. The precipitate that had formed was filtered, washed with MeOH, and the filtrate was concentrated under reduced pressure to give 2- (methoxyphenyl) -1-propylamine as a pale yellow oil (compound 2011, 144mg, 71% yield):¹H NMR(CDCl₃)7.27–7.13(m,2H),6.95(ddd,J＝18.2,12.3,4.6Hz,2H),3.84(s,3H),3.39–3.18(m,1H),2.86(qd,J＝12.7,6.8Hz,2H),1.44(s,2H),1.24(d,J＝7.0Hz,3H)。

a mixture of 4, 6-dichloropyrimidine (817mg,5.49mmol), 2- (2-methoxyphenyl) -1-propylamine (0.997g,6.03mmol) and DIEA (2.13g,2.87mL,16.5mmol) in isopropanol (5.0mL) was stirred for 18 hours as shown in scheme 4, step 4-v. The reaction mixture was concentrated under reduced pressure and the residue was purified by medium pressure chromatography on silica gel (25% EtOAc in hexanes) to give 6-chloro-N- (2- (2-methoxyphenyl) propyl) pyrimidin-4-amine as a colorless solid (compound 2012, 1.18g, 77% yield):¹H NMR(CDCl₃)8.31(s,1H),7.23(dd,J＝12.0,4.5Hz,2H),7.03–6.87(m,2H),6.41(s,1H),5.42(s,1H),3.89(s,3H),3.67–3.18(m,3H),1.35(d,J＝6.8Hz,3H)。

procedure as in scheme 44-vi 6-chloro-N- (2- (2-methoxyphenyl) propyl) pyrimidin-4-amine (75.0mg,0.270mmol), 1-methyl-4- [5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -2-pyridinyl]Piperazine (Compound 2007, 90.1mg, 0.297mmol), Pd (OAc)₂(1.21mg,0.00540mmol), [3- (2-dicyclohexylphosphinophenyl) -2, 4-dimethoxy-phenyl]Sodium sulfonate (VPhos,11.1mg,0.0216mmol) and Na₂CO₃A mixture of (405. mu.L, 2M,0.810mmol) in IPA (2mL) was treated with N₂(repeat 2 times) degassed and filtered back, then heated to 90 ℃ for 4 hours. The reaction mixture was filtered through celite and concentrated under reduced pressure. The residue was purified by medium pressure chromatography on silica gel (90-100% EtOAc in hexanes) to give N- (2- (2-methoxyphenyl) propyl) -6- (6- (4-methylpiperazin-1-yl) pyridin-3-yl) pyrimidin-4-amine as a clear yellow oil (compound 2013, 48.0mg, 42% yield):¹H NMR(CDCl₃)8.77(d,J＝2.2Hz,1H),8.56(s,1H),8.15(dd,J＝9.0,2.5Hz,1H),7.28–7.21(m,2H),7.01–6.89(m,2H),6.72(d,J＝9.0Hz,1H),6.60(s,1H),5.09(bs,1H),3.87(s,3H),3.76–3.65(m,4H),3.65–3.46(m,3H),2.62–2.48(m,4H),2.38(s,3H),1.36(d,J＝6.7Hz,3H)。

as shown in scheme 4, steps 4-vii, a chiral OJ column is used and CO is used₂Eluted with 40% MeOH (0.2% DEA), N- (2- (2-methoxyphenyl) propyl) -6- (6- (4-methylpiperazin-1-yl) pyridin-3-yl) pyrimidin-4-amine (30.0mg,0.0710mmol) was purified by supercritical fluid chromatography to give an off-white residue of (S) -N- (2- (2-methoxyphenyl) propyl) -6- (6- (4-methylpiperazin-1-yl) pyridin-3-yl) pyrimidin-4-amine (compound 32, 13.5 mg):¹H NMR(CDCl₃)8.77(d,J＝2.3Hz,1H),8.56(s,1H),8.14(dd,J＝9.0,2.5Hz,1H),7.28–7.18(m,2H),7.04–6.86(m,2H),6.71(d,J＝9.0Hz,1H),6.59(s,1H),5.24(d,J＝47.4Hz,1H),3.86(s,3H),3.75–3.64(m,4H),3.64–3.43(m,3H),2.65–2.47(m,4H),2.37(s,3H),1.36(d,J＝6.7Hz,3H)。

example 5. (S) -N- (2- (2-methoxyphenyl) propyl) -6- (6- (4-methylpiperazin-1-yl) pyridin-3-yl) pyrimidine Preparation of Pyrid-4-amine (Compound 2016)

The chirality of the asymmetric 1-carbon center of the 2-aminoethyl-B-ring moiety can be determined by the preparation of intermediates analogous to compound 2016 and the use of such intermediates in the preparation of the compounds of the present invention. Thus, the chirality of compound 34 was determined by preparing compound 2009 as a racemic mixture with a large enantiomeric excess biased towards the (S) -configuration. See Evans D.A. et al, J.Am.chem.Soc. (J.Am.Chem.Soc.) (J.Chem.Soc., 104, 1737-1739 (1982). Thus, as shown in step 5-i of scheme 5, 2- (2-methoxyphenyl) acetic acid (5.00g,30.1mmol) and Et are added at-15 deg.C₃Pivaloyl chloride (3.70g,3.78mL,30.7mmol) was added to a solution of N (6.70g,9.23mL,66.2mmol) in THF (150mL) and the resulting solution was stirred for 15 minutes. Lithium chloride (1.53g,36.1mmol) and (4S) -4-benzylOxazolidin-2-one (6.29g,35.5mmol) was added to the solution and the reaction was warmed to room temperature over 18 hours. Saturated ammonium chloride was added and the reaction was extracted with EtOAc (2 ×). The organic extracts were combined and washed with NaHCO₃(saturated), washed with brine, MgSO₄Dried, filtered and then concentrated under reduced pressure. The residue was purified by medium pressure silica gel chromatography (15 to 30% EtOAc in hexane) to give (4S) -4-benzyl-3- [2- (2-methoxyphenyl) acetyl]-Oxazolidin-2-one (compound 2014, 7.11g, 72.6% yield) as a white solid:¹H NMR(300MHz,CDCl₃)7.42–7.15(m,7H),6.96(dd,J＝15.6,7.8Hz,2H),4.79–4.65(m,1H),4.44–4.09(m,4H),3.85(s,3H),3.33(dd,J＝13.3,2.9Hz,1H),2.84(dd,J＝13.3,9.5Hz,1H)。

as shown in scheme 5, step 5-ii, (4S) -4-benzyl-3- [2- (2-methoxy-3) was added to a solution of sodium hexamethyldisilazane (NaHMDS,5.06g,26.2mmol) in THF (100mL) at-78 deg.C under a nitrogen atmospherePhenyl) acetyl group]Oxazolidin-2-one (7.11g,21.9mmol) and the reaction was stirred for 1.5 hours. Methyl iodide (3.08g,1.35mL,21.7mmol) was then added dropwise and stirring continued at-78 deg.C for 4 hours, after which the reaction was allowed to warm to room temperature over 18 hours. The reaction was cooled to-20 ℃ with NH₄Cl (saturated) quench. The organics were removed under reduced pressure and the aqueous layer was extracted with DCM (3 ×). The organic extracts were combined and washed with brine, MgSO₄Dried, filtered, and concentrated under reduced pressure. The residue was purified by medium pressure silica gel chromatography (5 to 25% EtOAc in hexane) to give (4S) -4-benzyl-3- [ (2S) -2- (2-methoxyphenyl) propanoyl]Oxazolidin-2-one as a white solid with a de value of 9:1 (S/R). Then, the mixture was subjected to Supercritical Fluid Chromatography (SFC) (10% MeOH/CO) on an IC column₂Isocratic gradient) to give (4S) -4-benzyl-3- [ (2S) -2- (2-methoxyphenyl) propanoyl]Oxazolidin-2-one (compound 2015, 3.14g, 41.8% yield) with 99.9% enantiomeric excess as determined by analytical SFC:¹H NMR(300MHz,CDCl₃)7.41–7.20(m,7H),6.96(dd,J＝13.8,6.6Hz,1H),6.93–6.84(m,1H),5.30(q,J＝7.1Hz,1H),4.68(qd,J＝6.7,3.5Hz,1H),4.22–4.11(m,2H),3.84(s,3H),3.35(dd,J＝13.3,3.2Hz,1H),2.82(dd,J＝13.3,9.7Hz,1H),1.64–1.46(m,3H)。

to (4S) -4-benzyl-3- [ (2S) -2- (2-methoxyphenyl) -propanoyl as shown in step 5-iii of scheme 5]Ice-cold solution of oxazolidin-2-one (3.10g,9.13mmol) in THF (183mL) and MeOH (1.24mL) LiBH was added₄(9.13mL of a 2.0M solution, 18.3mmol) and the reaction stirred at 0 ℃ for 2 hours and then warmed to room temperature over 18 hours. Solution of NaOH is added (18.6mL of a 2.0M solution) and the reaction was stirred until both layers were clear. Separate the layers and use Et₂The aqueous layer was O (2X) extracted. The organic extracts are combined and washed with H₂O, brine, and MgSO₄Dried, filtered, and concentrated. The residue was purified by flash chromatography on silica gel (0 to 20% EtOAc in hexanes) to give (2S) -2- (2-methoxyphenyl) propan-1-ol (compound 2016, 1.49g, 95.4% yield) as a clear colorless liquid:¹H NMR(300MHz,CDCl3)7.30–7.19(m,2H),6.98(td,J＝7.5,1.0Hz,1H),6.95–6.86(m,1H),3.85(s,3H),3.83–3.63(m,2H),3.56–3.38(m,1H),1.84(s,1H),1.30(d,J＝7.1Hz,3H)；[α]_D ²⁵ _. ⁷+4.18(c1.11,CHCl₃). This optical rotation is comparable to that of compound 2016 described in the following references: denmark SE et al, J.Am.chem.Soc. ((J.S. Chemicals Association), Vol.132, p.3612-3620 (2010), and MatsumotoT et al, Bull.chem.Soc.Jpn. ((Japanese society for chemical society), Vol.58, 340-345 (1985).

Compound 34, prepared as described in scheme 4 and resolved by preparative SFC separation at the end of the synthesis, was compared to the same compound prepared using chiral intermediate compound 1016 to determine its absolute stereochemical configuration.

Example 6. (S) -N- (2- (2, 3-dihydrofuro [3, 2-b)]Pyridin-7-yl) propyl) -6- (6- (methylamino) Preparation of pyridin-3-yl) pyrimidin-4-amine (Compound 430)

As shown in scheme 6, step 6-i, tert-butyl (2- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) allyl) carbamate (compound 1017, 1.455g, 5.138mmol), 7-chlorofuro [3,2-b ] amine]Pyridine (0.789g,5.138mmol), NaHCO₃(8.56mL,1.2M,10.276mmol), DMF (14.3mL) and H₂O (4.8mL) was combined. The resulting mixture was purged with nitrogen for 10 minutes. Addition of Pd (dppf) Cl₂(419.6mg,0.514mmol) and the reaction was heated to 120 ℃ for 30 minutes in a microwave. The crude reaction mixture was filtered through celite and the filter pad was washed with ethyl acetate. The combined organics were dried (Na)₂SO₄) And concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-20% EtOAc/hexanes) to provide (2- (furo [3, 2-b)]Pyridin-7-yl) allyl) carbamic acid tert-butyl ester (compound 1019, 0.94g, 67% yield): LCMS 275.26(M + H);¹H NMR(400MHz,CDCl₃)8.51(d,J＝5.0Hz,1H),7.86(d,J＝2.2Hz,1H),7.23(d,J＝4.8Hz,1H),7.01(d,J＝2.2Hz,1H),6.02(d,J＝15.6Hz,1H),5.69(s,1H),4.79(s,1H),4.34(d,J＝5.6Hz,2H),1.42(s,9H)。

as shown in step 6-ii of scheme 6, (2- (furo [3, 2-b))]Pyridin-7-yl) allyl) carbamic acid tert-butyl ester (0.940g,3.427mmol), Pd/C (10%, 364.7mg,3.427mmol), EtOAc (34.3mL) and MeOH (34.3mL) in a mixture of 0.1MPa (1 atmosphere) H₂Stirred for 16 hours. The reaction mixture was filtered through celite and the filter pad was rinsed with 1:1 EtOAc/MeOH. The combined filtrates were concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (0-100% EtOAc/hexanes) to provide (2- (2, 3-dihydrofuro [3, 2-b)]Pyridin-7-yl) propyl) carbamic acid tert-butyl ester (compound 1020, 0.711g, 75% yield): LCMS 279.47(M + H);¹H NMR(400MHz,CDCl₃)7.98(d,J＝4.8Hz,1H),6.86(d,J＝4.8Hz,1H),4.64(t,J＝8.8Hz,2H),4.54(s,1H),3.44–3.20(m,4H),3.13–3.00(m,1H),1.40(s,9H),1.24(d,J＝6.9Hz,3H)。

as shown in scheme 6, step 6-iii, tert-butyl (2- (2, 3-dihydrofuro [3,2-b ] pyridin-7-yl) propyl) carbamate (710mg,2.551mmol) was dissolved in HCl (19.13mL of 4M dioxane, 76.53mmol) and the reaction mixture was stirred for 10 minutes. The solvent was removed under reduced pressure and the resulting 2- (2, 3-dihydrofuro [3,2-b ] pyridin-7-yl) propane-1-amine x 2HCl (LCMS ═ 179.22[ M + H ]) was used as such in the following reaction.

As shown in step 6-iv of scheme 6, to 2- (2, 3-dihydrofuro [3, 2-b)]Pyridin-7-yl) propan-1-amine × 2HCl and 4, 6-dichloropyrimidine (456.0mg,3.061mmol) in i-PrOHEt (17.01mL) suspension to which Et was added₃N (1.291g,1.778mL,12.76 mmol). The reaction mixture was heated at 80 ℃ for 2 hours, cooled to room temperature, and quenched with saturated NaHCO₃Partition between aqueous and EtOAc further extract aqueous layer with EtOAc (2 × 50mL) and H₂The combined organics were washed with O (50mL) and brine (50mL) and dried (Na)₂SO₄) Filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-100% EtOAc/hexanes followed by isocratic EtOAc) to afford 6-chloro-N- (2- (2, 3-dihydrofuro [3, 2-b)]Pyridin-7-yl) propyl) pyrimidin-4-amine (600.3mg, 81% yield in two steps). Chiral SFC purification (5mL/min of 20% MeOH usingAD-H (4.6mm × 100mm) column, 10MPa (100 bar), 35 ℃, 220nm) to give (S) -6-chloro-N- (2- (2, 3-dihydrofuro [3,2-b ]]Pyridin-7-yl) propyl) pyrimidin-4-amine (compound 2021, 300mg, SFC retention time 1.05 min): LCMS 291.04(M + H);¹H NMR(400MHz,CDCl₃)8.32(s,1H),8.00(d, J ═ 4.5Hz,1H),6.92(d, J ═ 4.4Hz,1H),6.36(s,1H),5.24(s,1H),4.71(t, J ═ 8.9Hz,2H), 3.61-3.35 (m,4H),3.23(dd, J ═ 14.0,6.9Hz,1H),1.35(d, J ═ 6.9Hz, 3H). The corresponding (R) -enantiomer had a retention time of 1.25 minutes).

(S) -6-chloro-N- (2- (2, 3-dihydrofuro [3, 2-b) as shown in step 6-v of scheme 6]Pyridin-7-yl) propyl) pyrimidin-4-amine (29.2mg,0.1003mmol), N-methyl-5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyridin-2-amine (30.7mg,0.2006mmol), Na₂CO₃(150.4. mu.L of a 2M aqueous solution, 0.3009mmol) and i-PrOH (2.0mL) were combined and purged with nitrogen for 10 minutes. Add SPhos (water soluble, 10.28mg, 0.0201mmol) and Pd (OAc)₂(1.13mg,0.0050mmol) and the reaction vessel was sealed and heated to 120 ℃ for 30 minutes in a microwave. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. By reverse phase HPLC (0-30% CH)₃CN/H₂O, 0.1% TFA) purification of the residue. Using StratoShperses^TMPL-HCO₃MP-Resin column neutralizes the obtained TFA salt to provide (S) -N- (2- (2, 3-dihydrofuro [3 ],2-b]Pyridin-7-yl) propyl) -6- (6- (methylamino) pyridin-3-yl) pyrimidin-4-amine (compound 430, 23.8mg, 65% yield): LCMS 364.12(M + H);¹H NMR(400MHz,DMSO-d₆)8.83(s,2H),8.41(s,1H),7.90(d,J＝5.1Hz,1H),7.55(s,1H),7.39(s,1H),7.01(s,1H),6.77(s,1H),4.61(t,J＝8.4Hz,2H),3.66–3.40(m,2H),3.26–3.12(m,3H),2.86(d,J＝4.5Hz,3H),1.21(d,J＝6.6Hz,3H)。

example 7. (S) -N ⁶ - (2- (2, 3-dihydro- [1, 4)]II Endopho [2,3-b ]]Pyridin-8-yl) propyl) -N ^2' -first of all Radical- [4,5' -bipyrimidine]Preparation of (E) -2', 6-diamine (Compound 462)

As shown in scheme 7, step 7-i, N- (2-bromoallyl) -N-tert-butoxycarbonylcarbamic acid tert-butyl ester (22.0g,65.4mmol), 8- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -2, 3-dihydro- [1, 4-d-ydroxy-borane-2-yl ] -amide]IIEndopho [2,3-b ]]Pyridine (16.4g,62.3mmol) and sodium carbonate (13.2g,125mmol) in DME/H₂O (2:1,246mL) and the mixture was purged with nitrogen for 30 minutes. Adding 1,1' -bis (diphenylphosphino) ferrocene]After palladium (II) dichloride dichloromethane complex (1.53g,1.87mmol), the mixture was purged with nitrogen for an additional 5 minutes. The reaction mixture was heated at 85 ℃ for 2 hours, then MTBE (400mL) and water (100mL) were added. The organics were washed with brine, over MgSO₄Drying, filtering, concentrating under reduced pressure, diluting with minimal amount of DCM, and purifying by medium pressure silica gel chromatography (0-50% EtOAc/hexane) to give N-tert-butoxycarbonyl-N- [2- (2, 3-dihydro- [1,4 ] -ethyl hexanoate]IIEndopho [2,3-b ]]Pyridin-8-yl) allyl]Tert-butyl carbamate (compound 2022, 19g, 74% yield): ESMS 393.74(M + H);¹H NMR(300MHz,CDCl₃)7.75(d,1H),6.75(d,1H),5.30(s,1H),5.25(s,1H),4.55(s,2H),4.40(m,2H),4.25(m,2H),1.45(s,18H)。

as shown in step 7-ii of scheme 7, N-tert-butoxycarbonyl-N- [2- (2, 3-dihydro- [1, 4)]IIEndopho [2,3-b ]]Pyridin-8-yl) allyl]Tert-butyl carbamate (18.9g,48.2mmol) was stirred in EtOAc (200mL) with 10% palladium on charcoal (550mg,5.14 mmol). The reaction mixture was purged with an atmosphere replaced with hydrogen (3 ×) and stirred under a hydrogen atmosphere for 5 hours. The atmosphere was replaced with nitrogen and the mixture was filtered, concentrated to minimum volume under reduced pressure, and purified by medium pressure silica gel chromatography (0-100% EtOAc/hexanes) to give N-tert-butoxycarbonyl-N- [2- (2, 3-dihydro- [1,4 ] -ethyl hexanoate]IIEndopho [2,3-b ]]Pyridin-8-yl) propyl]Tert-butyl carbamate (compound 2023, 18.06g, 95% yield): ESMS 395.75(M + H);¹H NMR(300MHz,CDCl₃)7.75(d,1H),6.75(d,1H),4.45(s,2H),4.25(m,2H),3.65-3.80(m,3H),1.45(s,18H),1.25(3H)。

N-tert-Butoxycarbonyl-N- [2- (2, 3-dihydro- [1,4 ] -diluted with EtOH as shown in scheme 7, steps 7-iii]IIEndopho [2,3-b ]]Pyridin-8-yl) propyl]Tert-butyl carbamate (18.0g,45.6mmol) and an aliquot was purified by supercritical fluid chromatography usingIC preparation of a column (10mm × 250mm) with 40% CO₂EtOH elution was carried out at 35 ℃ and 10.1MPa (100 atmospheres) at a flow rate of 12 mL/min. The first peak was collected (retention time ═ 6.61 min). Combination of Chinese herbsAnd the first peak fraction was totalized and volatile substances were removed under reduced pressure to give (S) -N-t-butoxycarbonyl-N- [2- (2, 3-dihydro- [1, 4)]IIEndopho [2,3-b ]]Pyridin-8-yl) propyl]Tert-butyl carbamate (compound 2024, 7.74g, 43% yield, enantiomeric excess 97.9%)

(S) -N-tert-Butoxycarbonyl-N- [2- (2, 3-dihydro- [1,4 ] -as shown in step 7-iv of scheme 7]IIEndopho [2,3-b ]]Pyridin-8-yl) propyl]Tert-butyl carbamate (7.74g,39.8mmol) was dissolved in EtOH, HCl in IPA (60mL of 4M solution, 240mmol) was added and the reaction mixture was refluxed for 1 hour. The reaction mixture was concentrated under reduced pressure to minimum volume and Et was added₂O and the resulting suspension was stirred for 16 hours. The solid was collected by filtration and dried under high vacuum to provide (S) -2- (2, 3-dihydro- [1, 4)]IIEndopho [2,3-b ]]Yellowish solid of pyridin-8-yl) propane-1-amine dihydrochloride (compound 2025, 10.55g, 100% yield):¹H NMR(300MHz,CDCl₃)7.80(d,1H),7.10(d,1H),4.50(m,2H),4.40(m,2H),3.40(m,1H),3.00(m,2H),1.25(d,3H)。

(S) -2- (2, 3-dihydro- [1, 4) at 50 ℃ as shown in scheme 7, steps 7-v]IIEndopho [2,3-b ]]Pyridin-8-yl) propane-1-amine dihydrochloride (10.0g,49.5mmol), 4, 6-dichloropyrimidine (8.11g,54.5mmol), and TEA (15.03g,20.7mL,148.6mmol) were stirred in NMP (125mL) for 3.5 hours. The reaction mixture was cooled, 300mL of EtOAc were added, the organics were washed with water, and Na was added₂SO₄Dried, filtered, concentrated under reduced pressure, diluted with minimal DCM, and purified by medium pressure silica gel chromatography (0-100% EtOAc/hexanes). The product-containing fractions were concentrated under reduced pressureThis gave an oil which was dissolved in hot MTBE. The MTBE solution was cooled to produce a precipitate, which was collected by filtration and suspended in 4:1 hexane/MTBE. The solid was collected again by filtration to give 6-chloro-N- [2- (2, 3-dihydro- [1, 4)]IIEndopho [2,3-b ]]Pyridin-8-yl) propyl]Pyrimidin-4-amine (compound 2026, 10.78g, 71% yield): ESMS 307.21(M + H);¹H NMR(300MHz,CDCl₃)8.33(s,1H),7.78(d,J＝7.1Hz,1H),6.80(d,J＝7.1Hz,1H),6.40(s,1H),4.44(m,2H),4.34-4.21(m,2H),3.50(m,3H),1.31(d,J＝6.8Hz,3H)。

mixing 6-chloro-N- [2- (2, 3-dihydro- [1,4 ]]IIEndopho [2,3-b ]]Pyridin-8-yl) propyl]A part of the pyrimidin-4-amine was recrystallized from toluene, and the resulting crystals were analyzed by X-ray crystallography to confirm the (S) -configuration. X-ray powder diffraction (XRPD) showed peaks at 8.75, 10.30, 14.15, 17.50, 18.30, 18.80, 20.75, 20.95, 23.10, 23.95, 24.60, 26.20, 26.90, 29.20, 29.95, 30.45 and 31.95 (2-theta).

As shown in scheme 7, steps 7-vi, 6-chloro-N- [2- (2, 3-dihydro- [1,4 ] -c]IIEndopho [2,3-b ]]Pyridin-8-yl) propyl]Pyrimidin-4-amine (410mg) was dissolved in IPA (0.75 mL). N-methyl-5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyrimidin-2-amine (23mg) was added, followed by 2M Na₂CO₃(122. mu.L) and 1,1' -bis (diphenylphosphino) ferrocene]Palladium (II) dichloride dichloromethane complex (7 mg). The reaction vessel was sealed and heated at 80 ℃ overnight. The mixture was cooled, diluted with ethyl acetate, washed with water, and washed with Na₂SO₄Drying, filtering, concentrating under reduced pressure and passing through reverse phase HPLC, 5-50% ACN/H₂O/0.1% TFA purification. The fractions containing the pure product were collected, dissolved in MeOH and passed through a carbonate columnAnd concentrating under reduced pressure to provide (S) -N⁶- (2- (2, 3-dihydro- [1, 4)]IIEndopho [2,3-b ]]Pyridin-8-yl) propyl) -N^2'-methyl- [4,5' -bipyrimidine]-2', 6-diamine (compound 462): ESMS 380.39(M + H);¹h NMR (300MHz, methanol-d 4)8.75(s,2H),8.47(s,1H),7.65(d, J ═ 5.3Hz,1H),6.94(d, J ═ 5.2Hz,1H),6.76(s,1H),4.46-4.34(m,2H),4.32-4.19(m,2H),3.59(ddd, J ═ 12.0,11.5,7.3Hz,3H),2.99(s,3H),1.32(d, J ═ 6.7Hz, 3H).

Example 8. (S) -N- (2- (2, 3-dihydro- [1, 4)]II England [2,3-]Pyridin-8-yl) propyl) -6- (6-methyl Preparation of pyridylpyridin-3-yl) pyrimidin-4-amine (compound 443)

As shown in scheme 8, step 8-i, N- (2-bromoallyl) -6- (6-methyl-3-pyridyl) pyrimidin-4-amine (240mg, 0.7792mmol, compound 2027; prepared by reacting 4-chloro-6- (6-methylpyridin-3-yl) pyrimidine with 2-bromoprop-2-en-1-amine under basic conditions), 8- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -2, 3-dihydro- [1,4]IIEndopho [2,3-b ]]Pyridine (287.0mg,1.091mmol) and Na₂CO₃(1.169mL,2M,2.338mmol) was stirred in DMSO (5.945 mL). Addition of Pd (dppf) Cl₂(63.63mg,0.07792mmol) and the reaction mixture was stirred at 100 ℃ for 1h, then at room temperature for 16 h. After this time, the reaction mixture was partitioned between EtOAc and water, and the organics were taken up with Na₂SO₄Dried, filtered and the volatiles removed under reduced pressure. The residue was dissolved in DCM and chromatographed on medium pressure silica gel (20-100% Et)OAc/hexane followed by 0-10% MeOH/DCM) to yield N- (2- (2, 3-dihydro- [1, 4-dihydro- [ 1)]IIEndopho [2,3-b ]]Pyridin-8-yl) allyl) -6- (6-methylpyridin-3-yl) pyrimidin-4-amine (compound 2028) as a yellow oil: LCMS 362.37(M + H). This material was used as such in the subsequent reaction.

As shown in step 8-ii of scheme 8, N- [2- (2, 3-dihydro- [1, 4)]IIEndopho [2,3-b ]]Pyridin-8-yl) allyl]-6- (6-methyl-3-pyridinyl) pyrimidin-4-amine (150mg,0.4151mmol) was dissolved in MeOH and the reaction mixture was taken up in H₂Under an atmosphere. After stirring for 2 hours, the mixture was filtered, concentrated under reduced pressure, and purified by medium pressure silica gel chromatography (0-5% MeOH/DCM) to give N- (2- (2, 3-dihydro- [1,4 ] -dihydro- [1]IIEndopho [2,3-b ]]Pyridin-8-yl) propyl) -6- (6-methylpyridin-3-yl) pyrimidin-4-amine (compound 2029): LCMS 364.39(M + H);¹H NMR(300MHz,CDCl₃)9.00(d,J＝2.0Hz,1H),8.63(s,1H),8.20(dd,J＝8.1,2.3Hz,1H),7.81(d,J＝5.0Hz,1H),7.27(d,J＝4.2Hz,1H),6.82(d,J＝5.1Hz,1H),6.71(s,1H),4.43(dd,J＝5.1,3.0Hz,2H),4.27(dd,J＝5.1,3.0Hz,2H),3.56(m,3H),2.62(s,3H),1.32(d,3H)。

as shown in step 8-ii of scheme 8, N- (2- (2, 3-dihydro- [1, 4)]IIEndopho [2,3-b ]]Pyridin-8-yl) propyl) -6- (6-methylpyridin-3-yl) pyrimidin-4-amine by usingIC^TMColumn supercritical fluid chromatography (10mm × 250mm, 1/1 CO)₂EtOH, 35 ℃,12 mL/min, 10.1MPa (100 atmospheres)). Will retain timeThe first eluted product fractions at 11.08 min were combined to give (S) -N- (2- (2, 3-dihydro- [1, 4)]IIEngland [2,3-]Pyridin-8-yl) propyl) -6- (6-methylpyridin-3-yl) pyrimidin-4-amine (compound 443).

Example 9. (S) -N-methyl-8- (1- ((2 '-methyl- [4,5' -bipyrimidine)]-6-yl) amino) propan-2-yl) quine Preparation of quinoline-4-carboxamide (Compound 578)

To 4, 6-dichloropyrimidine in 1.68L DME (265.3g,1.781mol), CsF (241.5g,1.59mol) and 700mL of water were added as shown in step 9-i of scheme 9. The mixture was purged with nitrogen for 30 minutes and Pd (PPh) was added₃)₄(22.05g 19.08 mmol.) the resulting pale yellow solution is purged with nitrogen for a further 40 minutes, heated to reflux and a solution of 2-methyl-5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyrimidine (140g, 636.1mmol, 420mL DME) purged with nitrogen is added dropwise over 1.6 hours after which the resulting dark red solution is refluxed under nitrogen for 16 hours, after which time the mixture is cooled to room temperature and 300mL of water is added, then the mixture is cooled to 5 ℃ and stirred for 40 minutes, the resulting precipitate (6-chloro-2 '-methyl-4, 5' -bipyrimidine, Compound 9) is collected by filtration, washed with 50mL of water, then with 150mL of EtOAc, the filtrate is separated into two layers, the combined organics are extracted with Na 20378 EtOAc, the aqueous layer is extracted with EtOAc (2 × 1L)₂SO₄Dried, concentrated under reduced pressure, diluted with 300mL of DCM and purified by medium pressure silica gel chromatography (0-100% EtOAc/DCM). The fractions containing pure product were concentrated under reduced pressure and the concentrate was treated with 400mL of hexanes to yield compound 2039 as a solid. This material was combined with the previously collected solid product and treated with 400mL of 1:1 THF/DCM. Heating the obtained suspension and transferring the suspension into a containerThe filter funnel of the plug was washed with additional 1:1THF/DCM to dissolve any remaining solid material, then with 4:1EtOAc/DCM (2 × 1L.) the combined filtrates were concentrated under reduced pressure to give a pink solid, which was triturated with 500mL hexanes, collected by filtration, and dried under reduced pressure to afford 6-chloro-2 '-methyl-4, 5' -bipyrimidine (compound 2039, 88.8g, 68% yield): LC-MS ═ 207.01(M + H);¹H NMR(300MHz,CDCl₃)9.30(s,2H),9.10(d,J＝1.2Hz,1H),7.78(d,J＝1.2Hz,1H),2.85(s,3H)。

as shown in scheme 9, step 9-ii, 2-bromoaniline (520g,3.023mol) was melted in an oven at 50 ℃ and then added to a reaction vessel containing stirred acetic acid (3.12L). Methanesulfonic acid (871.6g,588.5mL,9.069mol) was then added over 15 minutes. The reaction mixture was heated to 60 ℃, methylvinyl ketone (377mL, 1.5 equivalents) was added over 5 minutes and the reaction mixture was stirred at 90 ℃ for 1 hour. After this time, another 50mL (0.2 eq) of methyl vinyl ketone was added and the reaction mixture was stirred for another 16 hours. The resulting dark brown solution was cooled with an ice-water bath and poured portionwise into a stirred solution of 50% w/w aqueous NaOH (3.894L,73.76mol) and ice (1kg), also cooled with an ice-water bath. Additional ice was added as needed during the addition to maintain the reaction temperature below 25 ℃. After the addition was complete, the reaction mixture (pH) was cooled while in an ice/water bath>10) Stir for 30 min. the precipitate formed was collected by filtration, washed with water (2L × 3) and dissolved in DCM (4L). Wash the organics with water (2L) and back extract the aqueous phase with DCM (1L). The combined organics were extracted with Na₂SO₄Dry, filter through a pad of silica gel (ca 2L), eluting with DCM then 3% EtOAc/DCM until all product passes through the plug the volatile material of the filtrate is removed under reduced pressure and the residue triturated with hexane (ca 500 mL.) the resulting solid is collected by filtration, washed with hexane (4 × 500mL) and dried in vacuo to give a light tan solid of 8-bromo-4-methylquinoline (compound 2030, 363g, 54% yield): LC-MS ═ 222.17(M + H);¹H NMR(300MHz,CDCl₃)8.91(d,J＝4.3Hz,1H),8.06(d,J＝7.4Hz,1H),7.99(d,J＝8.4Hz,1H),7.42(t,J＝7.9Hz,1H),7.30(d,J＝4.2Hz,1H),2.73(s,3H)。

selenium dioxide (764.7g,6.754mol) was absorbed in 3.25L of dioxane and 500mL of water as shown in scheme 9, steps 9-iii. The stirred solution was heated to 77 ℃ and 8-bromo-4-methylquinoline (compound 2030, 500g, 2.251mol) was added in one portion. The reaction mixture was stirred at reflux for 30 minutes and then cooled to about 45 ℃ with a water bath, at which temperature precipitation was observed. The suspension was filtered through celite, which was then washed with hot THF to dissolve any residual solids. The filtrate was concentrated to minimum volume under reduced pressure and 2M NaOH (2.81L,5.63mol) was added to obtain a pH of 8 to 9. The reaction mixture was stirred at the pH for 30 minutes. The resulting precipitate was collected by filtration and air-dried overnight to yield 8-bromoquinoline-4-carbaldehyde (compound 2031) as a pale yellow solid: MS 236.16(M + H);¹H NMR(300MHz,CDCl₃)10.52(s,1H),9.34(d, J ═ 4.2Hz,1H),9.05(dd, J ═ 8.5,1.2Hz,1H),8.18(dd, J ═ 7.5,1.3Hz,1H),7.88(d, J ═ 4.2Hz,1H),7.60(dd, J ═ 8.5,7.5Hz, 1H). This material was used as such in the subsequent reaction.

To a stirred suspension of 8-bromoquinoline-4-carbaldehyde (531.4g,2.25mol) in THF (4.8L) was added water (4.8L) and sodium dihydrogen phosphate (491.1g,4.05mol) as shown in step 9-iv of scheme 9. The mixture was cooled to 5 ℃ and the reaction temperature was kept below 15 ℃, sodium chlorite (534.4g,4.727mol) was added slowly as a solid in portions over about 1 hour. After the completion of the addition, the reaction mixture was stirred at 10 ℃ for 1 hour, and then 1N Na was added portionwise₂S₂O₃(1.18L) while maintaining the temperature below 20 ℃. The reaction mixture was stirred at room temperature, and then THF was removed under reduced pressure. The resulting aqueous solution containing the precipitate was taken up with saturated NaHCO₃(ca. 1L) treatment until pH. of 3 to 4 was obtained the mixture was stirred for an additional 15 minutes and the solid was collected by filtration, washed with water (2 × 1L), tert-butyl methyl ether (2 × 500mL) and dried in a convection oven at 60 ℃ for 48 hours additional drying under high vacuum provided 8-bromoquinoline-4-carboxylic acid (compound 2032530.7g, yield 94% from compound 1030) as a tan solid: LC-MS 252.34(M + H);¹H NMR(300MHz,DMSO-d₆)14.09(s,1H),9.16(d,J＝4.4Hz,1H),8.71(dd,J＝8.6,1.2Hz,1H),8.25(dd,J＝7.5,1.2Hz,1H),8.03(d,J＝4.4Hz,1H),7.64(dd,J＝8.6,7.5Hz,1H)。

as shown in scheme 9, step 9-v, to a suspension of 8-bromoquinoline-4-carboxylic acid (compound 2032, 779.4g, 3.092mol) in DCM (11.7L) was added anhydrous DMF (7.182mL,92.76 mmol). The reaction mixture was cooled to 10 ℃ and oxalyl chloride (413mL,4.638mol) was added dropwise over 30 minutes. After the addition was complete, the reaction mixture was stirred for an additional 30 minutes, transferred to an evaporation flask, and the volatiles were removed under reduced pressure. Anhydrous THF (2L) was added and the volatiles were removed again under reduced pressure to remove any residual oxalyl chloride. Anhydrous THF was added to the residue under a nitrogen atmosphere and the resulting suspension of intermediate 8-bromoquinoline-4-carbonyl chloride was saved for later use. Independently, the initial reaction flask was thoroughly purged with nitrogen to remove any residual oxalyl chloride and charged with dry THF (1.16L). After cooling to 5 ℃ an aqueous methylamine solution (2.14L of 40% w/w MeNH) was added₂Water, 24.74mol) and then additional THF (1.16L) was added. The intermediate acid chloride suspension was added to the solution in portions over 1 hour, during which time the reaction mixture temperature was maintained below 20 ℃. The evaporation vessel used to store the acid chloride was taken with anhydrous THF and aqueous MeNH₂(500mL) rinse and add it to the reaction mixture, allow the reaction mixture to return to room temperature over 16 hours the organic volatiles are removed under reduced pressure and the remaining predominantly aqueous suspension is diluted with water (1.5L) the solid is collected by filtration, washed with water until the filtrate has a pH of less than 11, washed with MTBE (2 × 800mL) and dried in a convection oven at 60 ℃ to provide a light brown solid of 8-bromo-N-methyl-quinoline-4-carboxamide (compound 2033, 740.4g, 90% yield): LC-MS ═ 265.04(M + H);¹H NMR(300MHz,DMSO-d₆)9.08(d,J＝4.3Hz,1H),8.78(d,J＝4.7Hz,1H),8.21(dd,J＝7.5,1.2Hz,1H),8.16(dd,J＝8.5,1.3Hz,1H),7.65(d,J＝4.3Hz,1H),7.58(dd,J＝8.5,7.5Hz,1H),2.88(d,J＝4.6Hz,3H)。

as shown in scheme 9, steps 9-vi, 8-bromo-N-methyl-quinoline-4-carboxamide (Compound 2033, 722g, 2.723mol) and N- [2- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) allyl]Tert-butyl carbamate (compound 2034, 925.4g, 3.268mol) was combined in the reaction flask. Adding Na₂CO₃(577.2g,5.446mol) and then water (2.17L) was added. The mixture was stirred for 5 minutes, 1, 4-dioxane (5.78L) was added and the mixture was deoxygenated by bubbling in a stream of nitrogen for 30 minutes. Addition of Pd (dppf) Cl₂/DCM (44.47g,54.46mmol) and deoxygenation continued as before for another 30 min. The reaction mixture was stirred at reflux for 16 h, allowed to cool to 70 ℃ and water (5.42L) was added. The mixture was further cooled with an ice-water bath and heated in<Stirring was continued for 2 hours at 10 ℃ the resulting precipitate was collected by filtration, washed with water (3 × 1L) and with TBME (2 × 1L), the resulting precipitate cake was divided into two equal portions, each portion was dissolved in THF/DCM (4L) and poured overOn a pad (3L filter funnel with about 1.5L florisil, pad wetted with DCM). The plug was then washed with MeTHF until no product remained in the filtrate as determined by thin layer chromatography. The filtrates from the two cake portions were combined and concentrated under reduced pressure to give an orange solid. TBME (1L) was added and the resulting suspension was filtered. The collected solid was washed with 800mL of TBME and dried under high vacuum overnight to provide tert-butyl (2- (4- (methylcarbamoyl) quinolin-8-yl) allyl) carbamate (compound 2035, 653g, 70% yield) as an off-white solid: LC-MS-342.31 (M + H);¹H NMR(300MHz,CDCl₃)8.93(d, J ═ 4.3Hz,1H),8.17(dd, J ═ 8.4,1.6Hz,1H),7.68-7.53(m,2H),7.41(d, J ═ 4.3Hz,1H),6.09(br.s,1H),5.54(s,1H),5.28(s,1H),5.10(br.s,1H),4.33(d, J ═ 6.0Hz,2H),3.11(d, J ═ 4.8Hz,3H),1.38(s, 9H). Additional product was obtained (34.9g, 74% overall yield) by: the filtrate was concentrated under reduced pressure, the residue was dissolved in THF, and the solution was filtered as beforeThe plug was washed with MeTHF, the filtrate was concentrated under reduced pressure, 250mL of TBME was added, stirred for 0.5 h, the resulting precipitate was collected by filtration, the solid was washed with EtOAc (40mL), acetonitrile (50mL), and the solid was dried under high vacuum overnight.

To a stirred suspension of tert-butyl (2- (4- (methylcarbamoyl) quinolin-8-yl) allyl) carbamate (compound 2035, 425g, 1.245mol) in EtOH (4.25L) was added 5.5M HCl in iPrOH (1.132L,6.225mol) as shown in scheme 9, steps 9-vii. The reaction mixture was stirred at reflux (internal temperature of 76 ℃) for 30 minutes and then allowed to cool to 40 ℃ over 90 minutes. EtOAc (2.1L) is added and the mixture is stirred for an additional 2 hours. The solid was collected by filtration, washed with EtOAc and dried under high vacuum to afford 8- [1- (aminomethyl) vinyl]-tan solid of N-methyl-quinoline-4-carboxamide dihydrochloride (compound 2036, 357.9g, 91% yield): LC-MS-242.12 (M + H);¹HNMR (300MHz, methanol-d)₄)9.07(d,J＝4.6Hz,1H),8.27(dd,J＝8.5,1.5Hz,1H),7.89(dd,J＝7.2,1.5Hz,1H),7.81-7.72(m,2H),5.85(s,1H),5.75(s,1H),4.05(s,2H),3.04(s,3H)。

As shown in scheme 9, steps 9-viii, 8- [1- (aminomethyl) vinyl group]-N-methyl-quinoline-4-carboxamide dihydrochloride (Compound 2036, 168.8g, 537mmol) was stirred in MeOH (1.688L) and TEA (114.2g,157.3mL,1.129mol) was added followed by BaSO₄5% Pd on (22.88g,10.75 mmol.) the atmosphere of the reaction mixture is replaced with hydrogen and the reaction is stirred under a hydrogen atmosphere of 0.1MPa (1 atm) for 16 hours after which time the hydrogen atmosphere is removed and the mixture is filtered through celite, concentrated under reduced pressure and treated with 800mL of water and 250mL of DCM the resulting biphasic mixture is stirred vigorously until most of the solids have dissolved to give a thick mixture which separates on standing the pH of the aqueous layer is checked and found to be 8 pH, the layer is washed with 3 × 500mL of DCM, the pH is adjusted to 14 with 500mL of 6N NaOH and extracted with another 500mL of DCM, then the aqueous solution is treated with 500g of NaCl and treated with another 500mL of DCMIt is extracted. The combined organics were washed with Na₂SO₄Drying, filtration and concentration under reduced pressure afforded 8- (1-aminopropan-2-yl) -N-methylquinoline-4-carboxamide [ Compound 2037 (racemic mixture) 104.2g, 80% yield]：LC-MS＝244.43(M+H)；¹H NMR (300MHz, methanol-d₄)8.94(d,J＝4.3Hz,1H),8.02(dd,J＝8.3,1.6Hz,1H),7.72-7.59(m,2H),7.50(d,J＝4.3Hz,1H),4.30(h,J＝7.0Hz,1H),3.04(dd,J＝12.7,7.0Hz,1H),3.01(s,3H),2.90(dd,J＝12.7,6.9Hz,1H),1.40(d,J＝7.1Hz,3H)。

The two racemates of 8- (1-aminopropan-2-yl) -N-methylquinoline-4-carboxamide (compound 137, 1380.5g) are separated by chiral HPLC as shown in scheme 9, steps 9-ix. Thus, a 260mL aliquot (6mg/mL) of the racemic mixture was loaded onto the Chiralpak AY^TMColumn (11cm × 25cm) and elution with acetonitrile (0.2% TEA) at a flow rate of 400 mL/min, eluting two main peaks, when purified by HPLC (Chiralpak AY-H)^TMColumn (4.6mm × 250mm), eluting with acetonitrile (0.1% isopropylamine) at a flow rate of 1 mL/min), peak 1 had a retention time of 7.7 minutes and peak 2 had a retention time of 12.2 minutes, the combined peak 2 fractions were collected and volatiles were removed under reduced pressure to give 8- [ (1S) -2-amino-1-methyl-ethyl]-N-methyl-quinoline-4-carboxamide (578.3g, 97.4% enantiomeric excess): specific rotation (10 mg/mL in MeOH, 100mm sample cell) + 24.20; LC-MS-244.19 (M + H);¹h NMR (300MHz, methanol-d₄)8.94(d, J ═ 4.3Hz,1H),8.02(dd, J ═ 8.3,1.6Hz,1H),7.72-7.59(m,2H),7.50(d, J ═ 4.3Hz,1H),4.30(H, J ═ 7.0Hz,1H),3.05(dd, J ═ 12.8,7.1Hz,1H),3.01(s,3H),2.90(dd, J ═ 12.7,6.9Hz,1H),1.40(d, J ═ 7.0Hz, 3H). By adding 5N HCl/IPA (220mL,1.100mol) to ice-cooled 8- [ (1S) -2-amino-1-methyl-ethyl]A stirred solution of-N-methyl-quinoline-4-carboxamide (244.5g,1.005mmol) in 980mL of 1:1MeOH/DCM to form the hydrochloride salt. Remove the ice bath and add 1470mL Et in portions₂And O. The precipitate was collected by filtration and Et₂O washes and drying under high vacuum to yield 8- [ (1S) -2-amino-1-methyl-ethyl]-N-methyl-quinoline-4-carboxamide hydrochloride (compound 2038, 275.8g 98.1% yield).

To 4-chloro-6- (2-methylpyrimidin-5-yl) pyrimidine (compound 2039, 60g, 290.4mmol) and 8- [ (1S) -2-amino-1-methyl-ethyl) as shown in step 9-x of scheme 9](iv) -N-methyl-quinoline-4-carboxamide hydrochloride (Compound 2038, 82.87g, 296.2mmol) in THF (600mL) A stirred solution of water (168.0mL) was added followed by 2MNa₂CO₃(aq) (363mL,726.3 mmol.) the reaction mixture was stirred at reflux for 16 h the resulting precipitate was dissolved by addition of 2M HCl, the solution was washed with DCM (3 × 500mL) then 6M NaOH was slowly added to achieve pH 7 the reaction mixture was stirred at room temperature for 1h the resulting precipitate was collected by filtration and washed with water (4 × 250mL) and IPA (4 × 125mL) then the solid was dried under high vacuum at 50 ℃ for 16 h to give (S) -N-methyl-8- (1- ((2 '-methyl- [4,5' -bipyrimidine)]-6-yl) amino) propan-2-yl) quinoline-4-carboxamide (compound 578, 102g, 85% yield) as a light tan solid: LC-MS-414.40 (M + H);¹H NMR(300MHz,DMSO-d₆,70℃)9.14(s,2H),8.95(d,J＝4.3Hz,1H),8.47(s,1H),8.34(br.s,1H),8.02(d,J＝8.4Hz,1H),7.74(d,J＝7.3Hz,1H),7.59(t,J＝7.8Hz,1H),7.50(d,J＝4.3Hz,1H),7.28(br.s,1H),7.04(s,1H),4.52(h,J＝7.0Hz,1H),3.83-3.66(m,2H),2.88(d,J＝4.4Hz,3H),2.68(s,3H),1.42(d,J＝6.9Hz,3H)。

example 10. (S) -N-methyl-8- (1- ((2 '-methyl-4', 6 '-didedeuterium- [4,5' -bipyrimidine)]-6-yl) amino group Preparation of propan-2-yl) quinoline-4-carboxamide (Compound 844)

As shown in scheme 10, step 10-i, tert-butyl (2- (4- (methylcarbamoyl) quinolin-8-yl) allyl) carbamate (compound 2035, 83g, 243.1mmol) was taken up in EtOH and stirred for 10 min. To this solution was added HCl/i-PrOH (5M,194.5mL,972.4mmol) at room temperature. The reaction mixture was allowed to warm to 60 ℃ and stirred for 2 hours. After cooling, the mixture was concentrated under reduced pressure, and then traces of water were azeotropically removed with toluene under reduced pressure. By usingTrituration of EtOAc provided a tan solid (74g), which was dissolved in a mixture of water/THF (415mL/300mL), sodium bicarbonate (61.27g,729.3mmol) was added portionwise at room temperature and the reaction mixture was stirred for 10 minutes after addition was complete, after cooling to 0 deg.C, acetic anhydride (68.81mL,74.45g,729.3mmol) in THF (120mL) was added dropwise, the reaction mixture was allowed to return to room temperature and stirred for 12 hours, the solid was collected by filtration and washed with MTBE (2 × 500mL) to give a white solid, the filtrate was extracted with EtOAc (4 × 500mL) and the combined extracts were washed with brine (100mL), Na was used to extract EtOAc (× mL) and the combined extracts were washed with MTBE (2mL 500mL)₂SO₄Dried, filtered, and concentrated under reduced pressure. The residue was triturated with MTBE (500mL) and the resulting solid combined with the solid collected by filtration to provide an off-white solid of 8- (3-acetamidoprop-1-en-2-yl) -N-methylquinoline-4-carboxamide (compound 2040, 42.4g total, 62% yield):¹HNMR(300MHz,DMSO-d₆)8.96(d,J＝4.3Hz,1H),8.72(d,J＝4.5Hz,1H),8.21-7.96(m,2H),7.69-7.56(m,2H),7.53(d,J＝4.3Hz,1H),5.35(d,J＝1.5Hz,1H),5.16(s,1H),4.30(d,J＝5.9Hz,2H),2.87(d,J＝4.6Hz,3H),1.80(s,3H)。

as shown in scheme 10, step 10-ii, 8- (3-acetamidoprop-1-en-2-yl) -N-methylquinoline-4-carboxamide (12.4g,43.77mmol) and cycloocta-1, 5-diene/(2R, 5R) -1- [2- [ (2R,5R) -2, 5-diethylphospholan-1-yl) in methanol (372.0mL) were reacted under a nitrogen atmosphere]Phenyl radical]Rhodium (+1) cation-triflate (Rh (COD) (R, R) -Et-DuPhos-OTf,316.3mg,0.4377mmol) were combined and warmed to 35-40 ℃ until the solid dissolved. The reaction mixture was placed in a hydrogenation apparatus, the atmosphere was replaced with hydrogen, and the mixture was stirred at 50 ℃ for 14 hours under 100p.s.i. hydrogen. After cooling to room temperature, the mixture is filteredThe bed was then washed with MeOH (2 × 50 mL.) the filtrate was concentrated under reduced pressure and any trace of water was removed by DCM azeotrope reduced pressure the residue was triturated with 20% DCM (2 × 100mL) in MTBE to give (S) -8- (1-acetamidopropan-2-yl) -N-methylquinoline-4-carboxamide (Compound 2041, 11.0g, 88% yield, 96%e.e.) off-white solid:¹H-NMR(300MHz,DMSO-d₆)8.97(d, J ═ 4.3Hz,1H),8.67(d, J ═ 4.7Hz,1H),7.97(dd, J ═ 8.1,1.5Hz,1H),7.88(t, J ═ 5.6Hz,1H),7.73-7.54(m,2H),7.52(d, J ═ 4.3Hz,1H),4.31(dd, J ═ 14.3,7.1Hz,1H),3.55-3.32(m,3H),2.86(d, J ═ 4.6Hz,3H),1.76(S,3H),1.28(d, J ═ 7.0Hz,3H), the enantiomers are determined by chiral HPLC (ChiralPac IC,0.46cm × 25cm, flow rate 1.0mL, 30 min, 20 min, 3 min, the time of the enantiomers of ethanol-diethyl ether (0.5 min), and the enantiomers are retained for 0.5 min.

As shown in scheme 10, step 10-iii, (S) -8- (1-acetamidopropan-2-yl) -N-methylquinoline-4-carboxamide (11.0g,38.55mmol) in 6M aqueous hydrochloric acid (192.7mL,1.156mol) was warmed to 60 ℃. After stirring at this temperature for 2 days, the reaction mixture was allowed to cool and an additional 20mL of 6M HCl was added. Stirring was continued for another 2 days at 70 ℃. The reaction mixture was cooled with an ice bath and the pH was adjusted to about 11 with 6M NaOH (aq). The aqueous mixture was extracted with 5% MeOH/DCM and the combined organic extracts were washed with water (60mL), brine (100mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure to provide the crude product as a tan solid. The solid was suspended in EtOAc (200mL), cooled to 3 ℃ with an ice bath and 6M HCl/i-PrOH (30mL) was added portionwise to produce a white precipitate, which was collected by filtration. The solid was washed with EtOAc (100mL) and dried under high vacuum to afford (S) -8- (1-aminopropan-2-yl) -N-methylquinoline-4-carboxamide dihydrochloride [ compound 2038, 7.8g, 61% yield, 95% purity (5% compound 2041) ] as a white solid. This material was used as such in the subsequent reaction.

As shown in step 10-iv of scheme 10, 8- [ (1S) -2-amino-1-methyl-ethyl]-N-methyl-quinoline-4-carboxamide hydrochloride (compound 2038, 24.0g, 72.86mmol) was taken up in THF (230mL) and water (40mL) and stirred for 5 min. Sodium carbonate (15.44g,145.7mmol) in 100mL water was added and the reaction mixture was stirred for 10 minutes. 4, 6-dichloropyrimidine (12.18g,80.15mmol) was added and the reaction mixture was heated at reflux for 2h at 66 ℃. Will be provided withThe reaction mixture was cooled to room temperature, diluted with 200mL EtOAc, the organic layer was separated and the aqueous layer was extracted with 100mL EtOAc. The combined organics were washed with water (60mL), brine (100mL), dried over Na2SO4, filtered through a bed of silica gel (100g), and concentrated under reduced pressure. The resulting crude product was triturated with 20% DCM in MBTE (200mL) then MBTE (200mL) to give (S) -8- (1- ((6-chloropyrimidin-4-yl) amino) propan-2-yl) -N-methylquinoline-4-carboxamide (compound 2042, 23.15g, 88% yield) as a white solid:¹H NMR(300MHz,DMSO-d₆,70℃)8.97(d,J＝4.3Hz,1H),8.38(s,1H),8.20(s,1H),8.03(d,J–8.5Hz,1H),7.71(d,J＝6.8Hz,1H),7.66-7.55(m,1H),7.52(d,J＝4.2Hz,2H),6.63(s,1H),4.46(dd,J＝14.1,7.1Hz,1H),3.67(s,2H),2.90(d,J＝4.6Hz,3H),1.40(d,J＝7.0Hz,3H)；[α]_D ²⁴＝44.77(c＝1.14,MeOH)。

as shown in step 10-v of scheme 10, to a compound in methanol-d₄(140.4mL) of a stirred solution of 4, 6-dichloro-2-methyl-pyrimidin-5-amine (14.04g,78.88mmol) was added formic acid-d₂(7.77g,161.7mmol) and Palladium Black (765mg, 7.19mmol in MeOH-d₄Medium wet), then triethylamine (16.36g,22.53mL,161.7mmol) was added. The reaction mixture was sealed in a tube and stirred at room temperature overnight. The mixture was then filtered and concentrated under reduced pressure. Addition of Et₂O (250mL) and the mixture was stirred at room temperature for 1 hour. The resulting solid was filtered and Et₂O (x2) washing. The filtrate was concentrated under reduced pressure to give 4, 6-dideuterio-2-methyl-pyrimidin-5-amine (compound 2043, 5.65g, 65% yield) as a pale yellow solid:¹H NMR(300MHz,DMSO-d₆)5.25(s,2H),2.40(s, 3H). This compound was used in the subsequent step without further purification.

To CH as shown in steps 10-vi of scheme 10₃4, 6-Dideuterium-2-methyl-pyrimidin-5-amine (5.35g,48.14mmol) in CN (192.5mL) copper dibromide (16.13g,3.38mL,72.21mmol) was added followed by tert-butyl nitrite (8.274g,9.54mL,72.21 mmol). After 1 hour, the reaction was filtered through celite with dichloromethane. The filtrate was washed with water/brine (1:1), the organic layer was separated, the aqueous layer was extracted with dichloromethane (2 ×), and the combined organic and aqueous layersThe celite was filtered through the organic layer and concentrated under reduced pressure. The crude product was purified by medium pressure silica gel column chromatography (0-10% EtOAc/hexanes) to give 5-bromo-4, 6-dideuterio-2-methyl-pyrimidine (compound 2044, 4.1g, 49% yield):¹h NMR (300MHz, methanol-d₄)2.64(s,3H)。

As shown in scheme 10, steps 10-vii, a mixture of 5-bromo-4, 6-didehydro-2-methyl-pyrimidine (8.5g,48.57mmol), bis (pinacolato) diboron (13.57g,53.43mmol) and KOAc (14.30g,145.7mmol) in 2-methyltetrahydrofuran (102.0mL) was degassed by purging with nitrogen. To which dichloro-bis (tricyclohexylphosphoranylphosphino) -palladium (PdCl) was added₂[P(cy)₃]₂1.01g,1.364mmol) and the reaction mixture was stirred in a sealed tube at 100 ℃ overnight. Filtering the mixture and mixing the filtrate withDMT-silica (SiliCycle, 0.58mmol/g, 3.53g) was stirred together for 1 hour. The mixture was filtered and concentrated under reduced pressure to give 2-methyl-4, 6-dideuterio-5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyrimidine (compound 2045, 13.6g, 72% purity, the major contaminant being pinacol) as a pale yellow oil:¹H NMR(300MHz,CDCl₃)2.75(s,3H),1.30(s, 12H). This compound was used in the subsequent step without further purification.

As shown in scheme 10, step 10-viii, (S) -8- (1- ((6-chloropyrimidin-4-yl) amino) propan-2-yl) -N-methylquinoline-4-carboxamide (2.542g,7.146mmol), 2-methyl-4, 6-dideutero-5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyrimidine (2.204g, 7.146mmol, 72 wt%), Na₂CO₃(10.72mL of 2M (aq), 21.44mmol) andDPP Pd (SiliCycle Co., 1.429g, 0.3573mmol) was taken up in dioxane (30.00mL), the solution was purged with nitrogen for 5 minutes, and the reaction mixture was stirred at 90 ℃ for 16 hours. Filtering the mixture with diatomaceous earth, concentrating under reduced pressure, dissolving in DMSOAnd by reverse phase chromatography (10-40% CH)₃CN/H₂O, 0.1% TFA). Product fractions were combined and DCM and MeOH were added followed by 1N NaOH until a pH of greater than 7 was obtained. The product solution was extracted with DCM (2 ×) and the combined extracts were extracted with Na₂SO₄Drying, filtering and concentrating under reduced pressure to obtain (S) -N-methyl-8- (1- ((2 '-methyl-4', 6 '-dideutero- [4,5' -bipyrimidine)]-6-yl) amino) propan-2-yl) quinoline-4-carboxamide (compound 844, 181mg, 28% yield) as an off-white solid:¹H NMR(300MHz,DMSO-d₆,70℃)8.95(d,J＝4.2Hz,1H),8.47(s,1H),8.35(s,1H),8.01(d,J＝8.4Hz,1H),7.74(d,J＝7.1Hz,1H),7.59(t,J＝7.8Hz,1H),7.50(d,J＝4.3Hz,1H),7.30(s,1H),7.03(s,1H),4.51(h,J＝7.2Hz,1H),3.78(m,2H),2.88(d,J＝4.6Hz,3H),2.68(s,3H),1.41(d,J＝7.0Hz,3H)。

example 11. (S) -N-methyl-8- (1- ((6- (6-methylpyridin-3-yl) pyrimidin-4-yl) amino) propan-2-yl) Preparation of quinazoline-4-carboxamides (Compound 971)

As shown in scheme 11, step 11-i, 1- (2-amino-3-hydroxyphenyl) ethanone (4.0g,26.5mmol) and formamide (20mL,45mmol) were heated at 180 ℃ for 45 minutes under microwave irradiation. After cooling, water was added and the reaction mixture was concentrated under reduced pressure. The residue was purified by medium pressure silica gel chromatography (2% MeOH/DCM) to give 4-methylquinazolin-8-ol (compound 2046, 3.81g, 90% yield) as a yellow solid. The product was used as such in the subsequent reaction.

As shown in scheme 11, step 11-ii, cesium carbonate (9.9g,40mmol) and N-phenyl-bis (trifluoromethanesulfonylimide (PhN (Tf))₂14.12g,39.52 mmol). The cooling bath was removed and the reaction mixture was stirred at room temperature overnight. The organics were washed with water, 5% HCl, then 5% NaHCO 3. The combined aqueous washes were back-extracted with DCM (3X) and the combinations were combinedNa for organic matter of (3)₂SO₄Drying, filtration, and purification by medium pressure silica gel chromatography (0-50% EtOAc/hexanes) afforded 4-methylquinazolin-8-yl trifluoromethanesulfonate (compound 2047, 8.60g, 93% yield) as a brown solid:¹H-NMR(300MHz,CDCl₃)9.33(s,1H),8.17(dd,J＝8.4,1.3Hz,1H),7.82(dd,J＝7.9,1.3Hz),7.70(t,J–8.1Hz),3.02(s,3H)；19F-NMR(282MHz,CDCl₃)-73.5。

as shown in scheme 11, steps 11-iii, trifluoromethanesulfonic acid 4-methyl quinazolin-8-yl ester (1.19g,4.07mmol) and selenium dioxide (1.0g,9.0mmol) were taken up in 15mL pyridine and the reaction mixture was stirred at 60 ℃ for 4 hours. The reaction mixture was diluted with 100mL of THF and O- (7-azabenzotriazol-1-yl) -N, N, N ', N' -tetramethyluronium hexafluorophosphate (HATU,3.1g,8.14mmol) was added. After stirring at room temperature for 30 min, a 2M methylamine/THF solution (5.0mL,10.0mmol) was added. The reaction mixture was stirred at room temperature for 1 hour and the volatiles were removed under reduced pressure. The residue was taken up in DCM and saturated NH₄And (5) washing with Cl. The aqueous wash was back-extracted with DCM (2 ×) and the combined organics were taken over Na₂SO₄Dried, filtered, and concentrated under reduced pressure. The residue was purified by medium pressure silica gel chromatography (0-100% DCM/hexane) to afford 4- (methylcarbamoyl) quinazolin-8-yl trifluoromethanesulfonate (compound 2048, 982g, 72% yield) as a yellowish solid: LC-MS-335.88 (M + H);¹H NMR(300MHz,CDCl₃)9.65(dd,J＝8.6,1.4Hz,1H),9.47(s,1H),8.27(s,1H),7.89(dd,J＝7.7,1.3Hz,1H),7.79(dd,J＝8.6,7.8Hz,1H),3.13(d,J＝5.1Hz,3H)；19F-NMR(282MHz,CDCl₃)-73.5。

as shown in scheme 11, steps 11-iv, N- [2- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) allyl]Carbamic acid tert-butyl ester (compound 2034, 990mg, 3.5mmol), trifluoromethanesulfonic acid 4- (methylcarbamoyl) quinazolin-8-yl ester (980mg,2.9mmol), Na₂CO₃(3mL of 2M (aq), 5.9mmol) and Pd (dppf) Cl₂A nitrogen purged solution of (119mg,0.14mmol) in DMF (35ml) was heated at 100 ℃ for 3 hours. After cooling to room temperature, the reaction was mixedThe compound was poured into water and extracted with EtOAc (3 ×). The extract was washed with brine (2 ×). The aqueous phase was re-extracted with EtOAc and the organic extracts were washed with brine (2 ×). The combined organics were washed with Na₂SO₄Dried, filtered, and concentrated under reduced pressure. The residue was purified by medium pressure silica gel chromatography (EtOAc/hexanes 0-50%) to afford tert-butyl (2- (4- (methylcarbamoyl) quinazolin-8-yl) allyl) carbamate (compound 2049, 392mg, 39% yield) as a yellowish solid. LC-MS-343.13 (M + H);¹h NMR (300MHz, chloroform-d) 9.47(dd, J ═ 8.6,1.4Hz,1H),9.30(s,1H),8.31-8.12(m,1H), 7.91? 7.81(m,1H),7.69(dd, J ═ 8.7,7.1Hz,1H),5.57(s,1H),5.31(s,1H),5.02(d, J ═ 8.1Hz,1H),4.36(dd, J ═ 5.3,2.0Hz,2H),3.10(d, J ═ 5.1Hz,3H),1.37(s, 9H).

A solution of tert-butyl N- [2- [4- (methylcarbamoyl) quinazolin-8-yl ] allyl ] carbamate (200mg,0.58mmol) in DCM (10mL) was treated with TFA (2mL) as shown in step 11-v of scheme 11. After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure and dried under high vacuum to provide 8- [1- (aminomethyl) vinyl ] -N-methyl-quinazoline-4-carboxamide trifluoroacetate salt (compound 2050, 207mg, 100% yield): LC-MS-243.07 (M + H). The product was used as such in the subsequent reaction.

As shown in scheme 11, steps 11-vi, to 4-chloro-6- (6-methyl-3-pyridyl) pyrimidine (70mg,0.289mmol), 8- [1- (aminomethyl) vinyl]-N-methyl-quinazoline-4-carboxamide trifluoroacetate salt (70mg,0.20mmol) and Na₂CO₃(92mg,0.86mmol) of the suspension was heated at 100 ℃ for 60 hours. After cooling, the volatiles were removed under reduced pressure, the residue was dissolved in DCM and the organics were washed with water. The aqueous phase was back-extracted with DCM (2 ×) and the combined organics were taken over Na₂SO₄Dried, filtered, and concentrated under reduced pressure. The residue was purified by medium pressure silica gel flash chromatography (0-6% MeOH/DCM) to afford N-methyl-8- (3- ((6- (6-methylpyridin-3-yl) pyrimidin-4-yl) amino) prop-1-en-2-yl) quinazoline-4-carboxamide (compound 2051, 48mg, 58% yield): LC-MS-412.09 (M + H);¹H NMR(300MHz,CDCl₃)9.46(dd,J＝8.7,1.5Hz,1H),9.35(s,1H),9.03(d,J＝2.4Hz,1H),8.61(d,J＝1.1Hz,1H),8.39-8.14(m,2H),7.84(dd,J＝7.1,1.5Hz,1H),7.68(dd,J＝8.7,7.1Hz,1H),7.27(d,J＝8.1Hz,1H),7.13(s,1H),6.24-5.93(m,1H),5.59(d,J＝1.6Hz,1H),4.64(d,J＝6.3Hz,2H),3.09(d,J＝5.1Hz,3H),2.63(s,3H)。

as shown in scheme 11, steps 11-vii, N-methyl-8- (3- ((6- (6-methylpyridin-3-yl) pyrimidin-4-yl) amino) prop-1-en-2-yl) quinazoline-4-carboxamide (48mg,0.12mmol) and Rh (COD) (R, R) -Et-DuPhos-OTf (3mg) in MeOH (2mL) were combined in a glass tube. The reaction mixture was purged with hydrogen and then stirred in a stainless steel Parr high pressure reactor at 60 ℃ under a 0.69MPa (100psi) hydrogen atmosphere for 24 hours. After cooling and replacement of the reaction atmosphere with nitrogen, the reaction mixture was filteredThe filtrate was concentrated under reduced pressure and the residue was purified by medium pressure silica gel chromatography (0-5% MeOH/DCM) to afford (S) -N-methyl-8- (1- ((6- (6-methylpyridin-3-yl) pyrimidin-4-yl) amino) propan-2-yl) quinazoline-4-carboxamide (compound 971, 25mg, 49% yield): LC-MS-414.07 (M + H);¹h NMR (400MHz, methanol-d)₄)9.29(s,1H),8.86(br.s,1H),8.80(dd,J＝8.6,1.3Hz,1H),8.37(d,J＝1.1Hz,1H),8.14(s,1H),8.04-7.87(m,1H),7.71(dd,J＝8.6,7.2Hz,1H),7.39(d,J＝8.2Hz,1H),6.71(br.s,1H),4.51(q,J＝7.1Hz,1H),4.10-3.60(m,2H),3.01(s,3H),2.58(s,3H),1.48(d,J＝7.0Hz,3H)。

Example 12. (S) -N-methyl-8- (1- ((2 '-methyl-4', 6 '-didedeuterium- [4,5' -bipyrimidine)]-6-yl) amino group Preparation of propan-2-yl) quinazoline-4-carboxamide (Compound 984)

As shown in scheme 12, step 12-i, 8- [1- (aminomethyl) ethenyl]-N-methyl-quinazoline-4-carboxamide trifluoroacetate (850mg,2.39mmol) was dissolved in THF (30 mL). The solution was taken up in Et₃N(2.4mL,17.5mmol) and trifluoroacetic anhydride (0.5mL,3.8 mmol). The reaction mixture was stirred at room temperature for 15 hours. The volatiles were removed under reduced pressure and the residue was suspended in water, extracted with EtOAc (3 ×), and the combined organics were extracted with Na₂SO₄Dried, filtered, and concentrated under reduced pressure. The residue was purified by medium pressure silica gel chromatography (0-100% EtOAc/hexanes) to afford N-methyl-8- (3- (2,2, 2-trifluoroacetamido) prop-1-en-2-yl) quinazoline-4-carboxamide (compound 2052, 783mg, 97% yield): LC-MS-338.99 (M + H). This material was used as such in the subsequent reaction.

As shown in scheme 12, step 12-ii, MeOH (35mL) and N-methyl-8- (3- (2,2, 2-trifluoroacetamido) prop-1-en-2-yl) quinazoline-4-carboxamide (700mg,2.07mmol) in Rh (COD) (R, R) -Et-DuPhos-OTf (50mg) were placed in a glass tube. The reaction mixture was purged with hydrogen and stirred in a stainless steel Parr high pressure reactor at 60 ℃ under a 0.69MPa (100psi) hydrogen atmosphere for 24 hours. After cooling, the reaction atmosphere was purged with nitrogen. The reaction mixture is filteredThe filtrate was concentrated under reduced pressure and the residue was purified by medium pressure silica gel chromatography (0-100% EtOAc/hexanes) to afford (S) -N-methyl-8- (1- (2,2, 2-trifluoroacetamido) propan-2-yl) quinazoline-4-carboxamide (compound 2053, 317mg, 45% yield): LC-MS-338.99 (M + H).

As shown in scheme 12, step 12-iii, (S) -N-methyl-8- (1- (2,2, 2-trifluoroacetamido) propan-2-yl) quinazoline-4-carboxamide (200mg,0.588mmol), K₂CO₃A solution of (406mg,2.94mmol) in MeOH (10mL) and water (0.5mL) was heated at 60 deg.C for 1 h. The reaction mixture was concentrated under reduced pressure and dried under high vacuum to provide (S) -8- (1-aminopropan-2-yl) -N-methylquinazoline-4-carboxamide (compound 2054). LC-MS: 245.09(M +), which was used as such in the following reactions.

Compound 2054 was suspended in iPrOH (10mL) and 4, 6-dichloropyrimidine (130mg,0.80mmol) was added as shown in step 12-iv of scheme 12. The suspension was brought to 90 deg.CThe mixture was heated for 1 hour. After cooling, the volatiles were removed under reduced pressure. The residue was dissolved in EtOAc, washed with water, and the aqueous phase was back-extracted with EtOAc (2 ×). The combined organics were washed with Na₂SO₄Drying, filtration, concentration under reduced pressure, and purification by medium pressure silica gel chromatography (0-50% EtOAc/hexanes) afforded (S) -8- (1- ((6-chloropyrimidin-4-yl) amino) propan-2-yl) -N-methylquinazoline-4-carboxamide (compound 2055, 153mg, 73% yield): LC-MS-354.97,357.00 (M + H);¹H NMR(300MHz,CDCl₃)9.55-9.16(m,2H),8.27-8.07(m,2H),7.87-7.70(m,1H),7.61(ddd,J＝8.7,7.2,3.8Hz,1H),4.35(q,J＝7.0Hz,1H),3.49(m,1H),3.02(dd,J＝5.1,1.7Hz,3H),1.42(d,J＝7.0Hz,3H)。

as shown in scheme 12, step 12-v, (S) -8- (1- ((6-chloropyrimidin-4-yl) amino) propan-2-yl) -N-methylquinazoline-4-carboxamide (60mg,0.27mmol), 2-methyl-4, 6-dideutero-5- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) pyrimidine (compound 2042, 96mg, 0.27mmol), 2M Na₂CO₃(aqueous solution) (0.3mL) and Pd (dppf) Cl₂(8mg) mixture in dioxane (5mL) was heated under microwave irradiation at 110 ℃ for 1 hour. The volatiles were removed under reduced pressure and the residue was suspended in water and extracted with EtOAc (3 ×). The combined organics were washed with Na₂SO₄Drying, filtration, concentration under reduced pressure, and purification of the residue by medium pressure silica gel chromatography (0-100% EtOAc/hexanes) afforded (S) -N-methyl-8- (1- ((2 '-methyl-4', 6 '-dideutero- [4,5' -bipyrimidine)]-6-yl) amino) propan-2-yl) quinazoline-4-carboxamide (compound 984, 85mg, 71%): LC-MS-417.13 (M + H);¹h NMR (300MHz, methanol-d₄)9.30(s,1H),8.80(dd,J＝8.5,1.3Hz,1H),8.40(d,J＝1.2Hz,1H),7.98(d,J＝7.2Hz,1H),7.71(dd,J＝8.6,7.3Hz,1H),6.77(s,1H),4.52(q,J＝7.1Hz,1H),3.95-3.76(m,2H),3.01(s,3H),2.74(s,3H),1.49(d,J＝7.0Hz,3H)。

Tables 1 and 2 provide structural and analytical characterization data for the compounds of the invention (blank cells indicate no testing).

TABLE 1

TABLE 2

Bioassay of Compounds of the invention

Example 12 DNA-PK inhibition assay

Compounds were screened for their ability to inhibit DNA-PK kinase using standard radiation assays. Briefly, in this kinase assay, it is known³³Terminal in P-ATP³³Transfer of P-phosphate to peptide substrate. The assay was performed in 384 well plates with a final volume of 50. mu.L per well containing approximately 6nM DNA-PK, 50mM HEPES (pH 7.5), 10mM MgCl₂25mM NaCl, 0.01% BSA, 1mM DTT, 10. mu.g/mL sheared double stranded DNA (available from Sigma), 0.8mg/mL DNA-PK Peptide (Glu-Pro-Pro-Leu-Ser-Gln-Glu-Ala-Phe-Ala-Asp-Leu-Trp-Lys-Lys-Lys, available from American Peptide company) and 100. mu.M ATP. Thus, the compounds of the invention were dissolved in DMSO to prepare 10mM initial stock. Serial dilutions were then made in DMSO to obtain the final solution for assay. In DMSO or DMSO0.75 μ L aliquots of inhibitor were added to each well, followed by addition of aliquots containing³³ATP substrate solution of P-ATP (available from Perkin Elmer). The reaction was started by adding the DNA-PK peptide and double stranded DNA. After 45 min, the reaction was quenched with 25 μ L of 5% phosphoric acid. The reaction mixture was transferred to MultiScreen HTS 384-well PH plates (available from Millipore) and allowed to bind for one hour and washed three times with 1% phosphoric acid. Add 50. mu.L of Ultima Gold^TMAfter the high efficiency scintillator (available from perkin elmer), the samples were counted in a Packard TopCount NXT type Microplate Scintillation Counter (Packard TopCount NXT Microplate science and luminescence Counter) (Packard BioScience). K was calculated using Microsoft excelSolver macro fitting data to a kinetic model of competitive tight binding inhibition_iThe value is obtained.

For inhibition of DNA-PK, each of compounds 1 to 983 had a K concentration less than or equal to 0.30 micromolar_i. For inhibition of DNA-PK, compounds 1, 8, 11, 16, 28, 30, 32, 34-38, 40-46, 55, 57, 60, 63, 73, 79-80, 82-87, 91-92, 94, 96-105, 107, 109-110, 114-123, 125-128, 130-142, 144-159, 165-168, 172-180, 182-183, 186, 188-189, 193-195, 197-206, 208-211, 213-215, 217-218, 220, 222-223, 225, 227-228, 232-233, 235-245-250, 252-266, 268-279, 287-290, 293-294, 296, 299, 303-304, 307-328, 331-333, 338-342, 345-, 654-86. 889-964 and 966-979 and 981-984 have K of less than 0.030 micromolar concentration_i。

Example 13. Effect on cell viability after irradiation

To evaluate the radiosensitizing effect of the compounds of the invention in combination with Ionizing Radiation (IR), a broad set of cell lines covering a variety of tumor cell types and genetic backgrounds was tested. Cells were incubated with DMSO or compound 578 for 30 minutes, then exposed to various doses of radiation (0, 0.5, 1,2,4, 6, 8, and 16 gray). Use ofCell viability was assessed on day 6 (Promega, Inc). EC generated in the Presence of DMSO or Compound 578 in combination with ionizing radiation₅₀The (gray) values are shown in table 3. Compound 578 has radiosensitizing effect on radiation-sensitive cancer cell lines, EC₅₀The variation range is 1.7 times to 10.6 times. The tested glioblastoma cell lines showed overall lower sensitivity to radiation alone and thus lower radiosensitisation when compound 578 was used in the present assay. In addition to the normal human fibroblast cell line HS68, only marginal radiosensitisation was observed in human fibroblast cell lines (HFL1, IMR90 and MRC5) as well as in the normal epithelial cell lines ARPE19, normal human bronchial epithelial cells (NHBE) and Smooth Airway Epithelial Cells (SAEC). In DNA-PK null SCID mouse cell lines, compound 578 had very low effect on cell viability as a single agent or in combination with radiation. These data indicate that DNA-PK inhibition results in broad radiosensitisation across many different tumor cell types.

Table 3. EC of Compound 578 on post-irradiation ₅₀ Influence of (2)

Failure to calculate EC for these cell lines₅₀Offset of

Example 14. In vivo efficacy

The in vivo efficacy of compound 578 was evaluated in a subcutaneous xenograft model of primary OD26749 NSCLC. The primary NSCLC tumors were obtained from patients with poorly differentiated adenocarcinomas and serially passaged in SCID mice prior to this study. Nude mice were surgically implanted with 150-mg fragments of OD26749 tumor at passage 3 (P3). Systemic ionizing radiation (IR, 2 Gray/treatment) was administered using a dicesium 137 source and reached approximately 350mm at the tumor³It is started. Tumor volumes were measured twice weekly during the course of the study. Anti-cancer efficacy is expressed as% T/C (tumor/control) and regression as% T/Ti (reduction in tumor volume compared to the initial tumor volume).

On day 19 post-implantation, compound 578[ at 16%In + HPMC/PVP]Orally (twice daily at 0 and 4 hours) and (once daily) 200mg/kg at 25, 50, 100 mg/kg. A single 2 gray dose of systemic ionizing radiation was given 15 minutes after compound administration. Control animals were orally dosed with vehicle twice daily (hours 0 and 4). The same protocol was repeated on day 26 post-implantation.

By day 30 post-implantation, compound 578 at 100mg/kg twice daily in combination with 2 gray systemic ionizing radiation had induced significant regression (% T/Ti of-3.1; P <0.001) compared to ionizing radiation alone, whereas the experimental groups at 25 and 50mg/kg twice daily and the experimental group at 200mg/kg once daily all exhibited significant tumor growth inhibition (% T/C of 25.6, 11.7 and 6.5, respectively).

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

Claims (18)

1. A compound represented by the formula:

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, which is a compound represented by the formula:

3. the compound according to claim 1, which is a pharmaceutically acceptable salt of a compound represented by the formula:

4. a pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

5. A pharmaceutical composition according to claim 4 comprising a compound according to claim 1, and a pharmaceutically acceptable excipient.

6. The pharmaceutical composition according to claim 4, comprising a pharmaceutically acceptable salt of the compound according to claim 1, and a pharmaceutically acceptable excipient.

7. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer in a patient.

8. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for increasing the sensitivity of a cell to an agent that induces DNA damage.

9. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for enhancing a therapeutic regimen for treating cancer in a patient.

10. A compound represented by the formula:

or a pharmaceutically acceptable salt thereof.

11. The compound according to claim 10, which is a compound represented by the formula:

12. the compound according to claim 10, which is a pharmaceutically acceptable salt of a compound represented by the formula:

13. a pharmaceutical composition comprising a compound according to claim 10, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

14. The pharmaceutical composition according to claim 13, comprising a compound represented by the formula

And a pharmaceutically acceptable excipient.

15. The pharmaceutical composition according to claim 13, comprising a pharmaceutically acceptable salt of a compound represented by the formula

And a pharmaceutically acceptable excipient.

16. Use of a compound according to claim 10, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer in a patient.

17. Use of a compound according to claim 10, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for increasing the sensitivity of a cell to an agent that induces DNA damage.

18. Use of a compound according to claim 10, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for enhancing a therapeutic regimen for treating cancer in a patient.